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Structural characterization of membrane proteins and antibody-antigen complexes using 
single particle electron microscopy 
Evan Michael Green 
Abstract 
Proteins are the macromolecular complexes responsible for carrying out the majority of 
cellular processes ranging from signal transduction to catalyzing metabolic reactions and DNA 
replication. Proteins are polymers made up of amino acids that adopt complex three-dimensional 
shapes which are critical for their function. To better understand the structure and function of 
proteins structural biologist use a wide variety of experimental tools including NMR spectroscopy, 
X-ray crystallography, and electron microscopy (EM). Until recently, the majority of our 
understanding of protein structure was derived from X-ray crystallography but recent 
technological advances in electron microscopy have made it possible to determine the structure of 
a wide range of proteins to near-atomic resolution. During my Ph.D. I have primarily been focused 
on studying the structure and function of membrane proteins and antibody-antigen complexes 
using both negative stain EM and cryogenic EM (cryoEM). 
The first chapter of this dissertation focuses on the utility of recombinant antibodies and 
their ability to probe protein structure and function in a wide variety of contexts. In particular, 
recombinantly expressed antibodies have a number of distinct advantages over those derived from 
the hybridoma approach. Of particular relevance to my thesis work I highlight the use of 
recombinant antibodies to study the structure of protein complexes with for single particle 
cryoEM.  
In the second chapter I describe the structural characterization of the two-pore channel 
TPC1 from Arabidopsis thaliana (AtTPC1). AtTPC1 is a voltage- and ligand-gated ion channel. 
 vii 
Previous structures of this channel revealed the first resting state of a voltage sensor in an intact 
ion channel. The work in this chapter expands on the previous research by mutating the luminal 
Ca2+ binding site shifting the open probably of the channel at 0 mV in order to chapter an activated 
voltage senor. Using single particle cryoEM, and a high-affinity recombinantly expressed antibody 
fragment, we determined two new structures of the voltage sensor. This information provided 
critical information about the voltage activation mechanism for ion channels and represented one 
of the first examples of a single voltage gated ion channel trapped in multiple conformations.    
In the third chapter I present some unpublished work on a new immunoprecipitation-based 
method to rapidly characterize recombinant antibodies identified from phage display libraries. This 
method takes advantage of the minimal sample requirements of negative stain EM in order to give 
information about the epitope that the Fab binds as well as an estimate for the relative affinity. The 
technique greatly increases the rate at which it is possible to go from a panning to selecting the 
most useful Fabs to be used for structure determination using single particle cryoEM.  
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Abstract  
Antibodies (Abs) are ubiquitous reagents for biological and biochemical research and are 
rapidly expanding into new therapeutic areas. They are one of the most important probes for 
determining how proteins function under normal and pathophysiological conditions. Abs are 
required for quantification of targets, detection of temporal and spatial patterns of protein 
expression in cells and tissues, and identification of interacting partners and their biological 
activities. Their remarkable specificity and unique binding properties can facilitate three-
dimensional structure determination using X-ray crystallography and electron cryomicroscopy. 
While hybridoma technology that involves animal immunization is often productive, many 
antigen targets do not generate useful Abs. This is particularly true if unique states of the target 
or critical non-immunogenic target sequences need to be recognized by the Abs. By using the 
methods of recombinant antibody generation, identification, and engineering, these ‘hybridoma-
refractory’ antigens can be readily targeted. Specific, reproducible, and renewable recombinant 
Abs are proving to be invaluable reagents in applications ranging from biological discovery to 
structure determination of challenging macromolecules.   
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Discussion 
Comparing hybridoma and recombinant antibodies 
Monoclonal, target-specific antibodies (Abs) are routinely developed through hybridoma 
technology1 or by biopanning with recombinant antibody libraries 2,3. For hybridoma antibody 
development, B-cells from animals are harvested several weeks after they have been inoculated 
with the antigen. Immortalized hybridoma cells are generated through the fusion of B-cells with 
a myeloma cell line. Each hybridoma cell normally secretes a single species of immunoglobulin 
G (IgG) and the secreted IgGs are used in binding assays, such as ELISA or FACS, to select for 
cell lines producing antigen binders4,5. Since the antibody generation and affinity maturation 
occurs in vivo through the animals immune response, these Abs can have high specificity and 
affinity6.  
A common theme in any antibody campaign is that the investigator will ‘get what they 
screen for’. A significant drawback of hybridoma antibody campaigns is that the antigen will 
undergo proteolytic degradation to initiate the antibody-generating immune response (Fig 1) and 
the derived Abs may not recognize the native form of the antigen. Another disadvantage is that 
the Fragment of antigen-binding domain (Fab) (Fig 2) obtained by IgG proteolysis7 may not 
retain the same antigen-binding properties as the IgG. A polypeptide sequence that does not 
generate an immune response or three-dimensional epitopes can make antigens particularly 
hybridoma-refractory. Furthermore, the utility and reliability of numerous commercial Abs, 
many of which are generated through hybridoma technology, can be limited since the specificity 
and cross reactivity of Abs vary from vendor-to-vendor and lot-to-lot8. 
Many of the pitfalls of hybridoma antibody generation are resolved through biopanning with 
recombinant antibody libraries9,10. These libraries are generated by cloning synthetic or naive 
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Fabs, single-chain variable fragments (scFvs), or nanobodies (Nbs) (Fig 2) into phage or yeast 
display vectors11–14. Antigen-binding Abs are enriched through several rounds of selection by 
solid-phase2 or by flow cytometry15,16 (Fig 1). Biopanning parameters can be selected for the 
desired antibody-antigen binding conditions. The ability to counter select against non-desired 
epitopes is a particularly powerful advantage of the biopanning approach. Counter selection can 
be accomplished using different conformation states, homologues, or specific domains14,17. Since 
the entire process is done in vitro, temperature, buffer conditions, antigen ligand concentrations, 
and oligomeric assembly can be readily controlled. With proper selection conditions, the antigen 
has a much lower chance of being altered through the recombinant biopanning process compared 
to the hybridoma approach of animal inoculation. Recently, advances in automating the 
recombinant antibody biopanning process has greatly reduced the effort, time, and cost 
required18.  
Another advantage of using a recombinant antibody library is that binders from the 
biopanning process can be easily characterized through DNA sequencing. Once the sequence of 
the antibody is known it is essentially immortalized, renewable, and can be produced in 
recombinant expression systems. Recombinant expression of Fabs, scFVs, and Nbs in 
Escherichia coli is a fraction of the cost of hybridoma Abs generation19. Recombinant Abs can 
be engineered to have additional functionalities including tags for purification or 
immunoprecipitation, conjugation sites to increase chemical space, or mutagenesis to map the 
determinants of antigen recognition.  The antibody sequence allows for in vitro affinity 
maturation, mimicking an immune response, to select Abs with higher affinity and lower off-
rate20. Abs derived from recombinant affinity maturation campaigns often have affinities 10-50 
times higher than their parent21. Engineering of therapeutic antibody candidates can improve 
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their pharmaceutical effects, such as prolongation of half-life to increase their efficacy22. Further 
efforts to develop therapeutic Abs that take advantage of recombinant technologies have recently 
been reviewed23. 
 
Functional applications of recombinant antibodies 
Since the advent of biopanning by phage and yeast display, recombinant Abs have 
become invaluable reagents for therapeutics, imaging, and understanding protein-protein 
mediated mechanisms of action (Fig 2). Therapeutic Abs typically prevent binding of ligands to 
receptors by either blocking the ligand or the receptor24. Abs against the immune checkpoint 
protein programmed death (PD-1) and its ligand (PD-L1) are recent examples25. Currently, there 
are several antibody therapeutics against these two targets for various cancer treatments that are 
either approved or in clinical trials26, indicating the importance of this growing field. And with 
this, the development of tools for preclinical assessment of patient responses to immunotherapy 
is also emerging, such as immunopositron emission tomography (immunoPET)27 where Abs 
towards the immune checkpoint proteins are conjugated with a radiotracer and used for in vivo 
imaging. 
Recombinant Abs that recognize specific states of a protein can potentially be used as 
diagnostic tools. An example of this is a recombinant active-site-specific Fab developed for the 
transmembrane serine protease, matriptase17. Active matriptase is a biomarker for tumorigenesis. 
The recombinant Fab distinguished cancer from non-cancer cell lines in vitro and in colon cancer 
sections from human tissue micro arrays. In vivo imaging of colon cancer patient-derived 
xenograft models showed tumor uptake of the radio-labelled antibody, indicating that this Fab 
could be used for noninvasive tumorigenesis evalution28.  
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Abs are also used for exploring the roles of specific intercellular and extracellular 
proteins. Blocking protein-protein interactions by Abs can help dissect the mechanism of action 
of the target of interest. By converting Abs to scFvs, intracellular signaling pathways can be 
probed since scFvs are properly folded in the reducing cytoplasmic environment, whereas IgGs 
and Fabs are not.  An example of this is the intracellular expression of an scFv which was 
generated against β-arrestins (βarrs), an important regulator of GPCR (G protein-coupled 
receptor) signal transduction29. This scFv selectively disrupts βarrs/clatherin interaction and 
inhibits agonist-induced endocytosis of GPCRs without affecting other molecular pathways. 
Another such example of Fab-based modulation is of the Vif protein complex, which is an HIV 
protein complex that counteracts the antiviral effects of the host apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide 3 (APOBEC3) immune proteins30. In vitro experiments with the 
Fabs, and in vivo experiments with transiently expressed scFvs, showed that Vif uses a multi-
pronged approach involving both degradation-dependent and -independent mechanisms to 
suppress APOBEC3-innate immunity. 
Cell classification and profiling, using a technique referred to as phage-antibody next 
generation sequencing (PhaNGS)31, demonstrated yet another innovative use of recombinant 
Abs.  In this technique, a collection of defined Fabs that bind specifically to previously identified 
targets of interest are displayed on phage and pooled to make a customized library. Fab-phage 
bound to cells are identified through next-generation sequencing of a barcode region in the Fab. 
It is expected that PhaNGS will be useful for observing surface protein changes in disease-state 
cells and for identification of new combinatorial biomarkers and drug targets. 
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Recombinant antibodies in X-ray crystallography 
Abs are used extensively in structural biology to help determine high-resolution structures of 
antibody-antigen complexes owing to their ability to facilitate crystal packing of challenging targets, 
act as a fiducial marker to aid in particle orientation in electron microscopy (EM), and trap specific 
conformational states (Fig. 2). In the following sections, we highlight the broad utility of Abs for 
structural studies with a particular emphasis on recombinant Abs.  
In order to determine the three-dimensional structure of a protein using X-ray 
crystallography, it is necessary to generate well-ordered crystals that diffract to high resolution. For 
this to occur, crystal contacts must be made between individual macromolecules to generate a three-
dimensional lattice. Formation of crystal contacts can be impeded by a lack of suitable exposed 
surface area or by conformational flexibility. This is particularly true of detergent-solubilized 
membrane proteins as the detergent micelle often precludes crystal contacts between transmembrane 
helices32. Abs have been used to assist in the crystallization of membrane proteins since it was 
observed that the lattice contacts of membrane-protein crystal structures are often mediated by polar 
surfaces33. In the case of the potassium channel KcsA co-crystallization with a Fab was necessary to 
achieve the resolution required to assign potassium ion coordination in the central pore34.  
While early antibody-assisted crystallization studies used hybridoma derived Abs, there are a 
number of significant advantages for recombinant Abs. Since full length IgGs are typically too 
flexible to generate well-ordered crystals, Fabs must be generated through proteolytic cleavage, 
which is not required with recombinant Abs. For most labs, purification of the milligram quantities of 
recombinant Abs required for a crystallography campaign is more straightforward and reproducible 
compared to hybridomas-based expression and purification. Conformationally-specific Abs are easier 
to generate with recombinant approaches given the in vitro nature of the biopanning method making 
it possible to select for Abs in the presence of ligands or binding-partners. Recombinant Abs have 
been used extensively in GPRC structural biology making it possible to trap active states and 
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complexes with interaction partners35,36. Use of recombinant Abs is not restricted to membrane 
proteins as they have been used for co-crystallization of a number of soluble proteins including a 
module of the polyketide synthetase 6-deoxyethronolide B synthase37 and matriptase38,39. To increase 
the utility of recombinant Abs for X-ray crystallography, recent work has been done to engineer the 
scaffold with desired properties, such as the use of ‘elbow locking’ mutations to rigidify the link 
between the constant and variable domains to increase crystallizability40.  
 
Recombinant antibodies in cryoEM 
Recent advances in electron cryomicroscopy (cryoEM) have made it possible to solve near-
atomic resolution structures of proteins41. While several well-behaved samples have achieved 
resolutions better than 2 Å, achieving the resolution required to build de novo models for new 
samples is still challenging42. Before the ‘resolution-revolution’, Abs were used as fiducial markers 
for EM by immunogold labeling43 but more recently the use of recombinant Fabs as fiducial markers 
for single-particle cryoEM of small and challenging targets was demonstrated44. This technique has 
been used to determine a number of high resolution structures that were recalcitrant to high-
resolution structure determination without a Fab 45,46. Fabs have a number of advantages for this task. 
Unlike other methods of increasing molecular weight, such as green fluorescent protein or maltose-
binding protein fusions47, Fabs can specifically recognize and bind rigid three-dimensional epitopes 
thereby facilitating high-resolution refinement44.  
The characteristic shape of Fabs in both negative stain and cryoEM provides a means for 
assessing the quality of medium-low resolution structures in addition to high-resolution alignment44. 
As is the case with X-ray crystallography, recombinant Abs have also been crucial for the structure 
determination of several GPCR complexes48–51, integrin52, and ABC transporters53 by trapping 
specific conformations. In addition to conformational selectivity, Fabs can alter the orientation 
distribution of vitrified samples. In the recent structure of TMEM16A, a calcium-activated chloride 
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channel, the sample in detergent had a significant preferred orientation bias resulting in a structure 
with anisotropic resolution54. By merging datasets with and without a Fab, it was possible to increase 
the resolution from 3.8 to 3.4 Å, as the two samples had different orientation distributions resulting in 
a final structure that was more isotropic and higher-resolution.  
The low signal-to-noise ratio of cryoEM data makes refinement of psuedosymmetric 
complexes particularly challenging as protomers may not align properly if differences between them 
are small. Fabs have been used to overcome this problem in several systems as a symmetry-breaking 
fiducial mark. For example, Fabs against the heterodimeric ABC transporter TmrAB were used to 
increase the molecular weight of the relatively small membrane protein while simultaneously 
breaking a pseudo two-fold symmetry allowing for the unambiguous assignment of the individual 
protomers55. In the case of TmrAB, the estimated angular accuracy was significantly higher for the 
TmrAB-Fab complex relative to the apo sample. This same approach has been applied to several 
heteromeric ion channels56,57. Future engineering of antibody scaffolds may specifically tailor them 
to the unique requirements of single particle cryoEM with reduced flexibility and increased desired 
orientation distributions58. Since the theoretical minimum molecular weight required for high-
resolution alignment is estimated to be around 50 kDa, approximately the same molecular weight of 
a Fab, it is conceivable that any Fab-antigen complex will be suitable for cryoEM in the future59.  
 
Conclusions 
The lack of high-quality Abs for many macromolecules and their complexes limits our ability 
to determine protein structure, to detect proteins in pathology samples, and to image and treat 
diseases. The availability of potent, specific, reproducible, and readily renewable probes for the 
entire proteome, including hybridoma-refractory antigens, could transform the study of biology and 
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enable the discovery of new therapeutics. Recombinant antibody technology, in addition to existing 
hybridoma techniques, provides a robust pipeline for the generation of these essential reagents.  
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Figure 1.1: Antigen presentation in hybridoma antibody generation versus recombinant 
antibody display. Target antigen (red) follows hybridoma immunoglobulin G generation path (top) 
or recombinant antibody (rAb) generation path (bottom). In top path, the pink cell is a major 
histocompatibility complex (MHC) presenting cell, the purple cell is a T-cell, the blue cell is a B-cell, 
the black receptor is a MHC, and the grey receptor is a T-cell receptor (TCR). In bottom path, the 
grey oval particles are display library members (yeast or phage) with colored displayed rAb and the 
yellow cell is Escherichia coli. 
 12 
 
Figure 1.2: Different formats and important applications of recombinant antibodies. 
Various antibody formats are shown in the center of the circle: immunoglobulin G (IgG), fragment of 
antigen-binding domain (Fab), single-chain variable fragment (scFv), and nanobody (Nb). IgGs are 
composed of two unique polypeptide chains, a heavy chain (H) and a light chain (L) based on their 
molecular weights. Each chain has one variable region (VH, VL). The light chain has one constant 
region (CL) and the heavy chain has three constant regions (CH1-3). Two heavy chains and two light 
chains come together to make an IgG. A Fab is composed of VH, VL, CH1 and CL. An scFv is a single 
polypeptide chain composed of both VH and VL connected with a flexible linker. A Nb consists of 
only a VH. Heavy chains are colored in dark blue, light chains are colored in cyan, and antibody 
targets are colored in red. 
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Abstract 
Voltage sensing domains (VSDs) couple changes in transmembrane electrical potential to 
conformational changes that regulate ion conductance through a central channel. Positively 
charged amino acids inside each sensor cooperatively respond to changes in voltage. Our 
previous structure of a TPC1 channel captured the first example of a resting-state VSD in an 
intact ion channel. To generate an activated state VSD in the same channel we removed the 
lumenal inhibitory Ca2+-binding site (Cai2+), that shifts voltage-dependent opening to more 
negative voltage and activation at 0 mV. Cryo-EM reveals two coexisting structures of the VSD, 
an intermediate state 1 that partially closes access to the cytoplasmic side, but remains occluded 
on the lumenal side and an intermediate activated state 2 in which the cytoplasmic solvent access 
to the gating charges closes, while lumenal access partially opens. Activation can be thought of 
as moving a hydrophobic insulating region of the VSD from the external side, to an alternate 
grouping on the internal side. This effectively moves the gating charges from the inside potential 
to that of the outside. Activation also requires binding of Ca2+ to a cytoplasmic site (Caa2+). An 
X-ray structure with Caa2+ removed and a near-atomic resolution cryo-EM structure with Cai2+ 
removed define how dramatic conformational changes in the cytoplasmic domains may 
communicate with the VSD during activation. Together four structures provide a basis for 
understanding the voltage dependent transition from resting to activated state, the tuning of VSD 
by thermodynamic stability, and this channel’s requirement of cytoplasmic Ca2+-ions for 
activation. 
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Introduction 
Voltage sensing domains (VSDs) are four-helical bundle domains,  termed S1-S4 that 
respond to changes in membrane potential by allowing ‘gating’ charges, generally positively 
charged arginine or occasionally lysine side chains in the fourth transmembrane helix S4 
(charges referred to as R1-R5) to move relative to a charge-transfer center (CT) 1,2 that contains 
counter charges in the surrounding helices S1-S3 and an aromatic residue (Y, F) that seals the 
VSD to solvent passage.  
The number of gating charges in each VSD that move across the membrane from 
connection to the cytoplasmic side to the extracellular (or lumenal) side during activation is 
typically measured as 2-3 and up to 5 positive charges. The basis for structural and electrical 
changes in S4 that give rise to voltage-dependence is key to understanding the response of 
voltage-gated ion channels to changes in membrane potential.  
In voltage-gated ion channels, the movement of S4 is connected via an S4-S5 linker helix 
on the cytoplasmic side to the pore helices S5-S6 of the ion channel, and also through Van der 
Waals hydrophobic contacts between S4 and the pore-forming domains. In excitable cells, 
activation of the VSD in response to membrane depolarization greatly increases the probability 
of channel opening3,4. 
 Several models have been proposed for voltage-dependent activation. The ‘Sliding 
Helix’5, ‘Rotating helix’6,7, and ‘Paddle’8 models suggest that S4 moves substantially (vertically 
or in rotation) in the membrane to translate the gating charges across the membrane (SI 
Appendix, Fig. S1). In Sliding Helix and Rotating Helix models, the gating charges interact with 
counter anions or aqueous environments to avoid the energetic penalty of placing a charge in a 
hydrophobic environment. Lanthanide-based resonance energy transfer measurements suggest 
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that gating charges do not move extensively during activation, but rather achieve alternating 
exposure to the internal and external milieu through conformational changes in the VSD helices 
S1-S4 9. A ‘ratchet’ model also includes the possibility of multiple intermediate states of S410. 
Electrophysiology, electron paramagnetic resonance (EPR) spectroscopy, X-ray structures, 
disulfide crosslinking, and simulations support a combination of translation and rotation of S4 
during activation 11–18. No structural information until now exists for voltage-gated channels 
captured in multiple activation states, precluding an atomic scale evaluation of the mechanism of 
voltage-dependent changes, or how they translate to channel activation.  Our previous crystal 
structure of wild-type Arabidopsis thaliana two-pore channel 1 (AtTPC1WT) provided the first 
resting-closed state in an intact ion channel19,20, the electrophysiological state that forms under 
high lumenal 1 mM (>100µM) Ca2+-ion concentration. Here we sought to determine structures 
for the activated-state of AtTPC1 that is formed in low lumenal (<100µM) Ca2+-ions by 
removing the inhibitory lumenal Ca2+-binding site in VSD2 (Cai2+), while keeping the 
cytoplasmic activation site (Caa2+) occupied with >300µM cytoplasmic Ca2+-ions 21. Secondly, 
we wanted to determine the mechanism for the channel’s requirement of cytoplasmic Ca2+-ions 
for activation by removing the Caa2+ site.  
 TPCs are a family of ion channels that regulate ion conductance across endolysosomal 
membranes22,23,21. Located in endosomes that endocytose from the plasma membrane, initially 
with ~1mM extracellular Ca2+ concentration, they regulate the conductance of Na+- and/or Ca2+-
ions out of the endolysosome, intravesicular pH 24, trafficking 25, and membrane excitability 26. 
Cytoplasmic Ca2+-ions (>300 µM) are required for any activation of AtTPC1 27, whereas 
lumenal Ca2+-ions (>100 µM) suppress voltage-dependent activation 20,28. TPCs encode two 
pore-forming domains on a single chain with two non-equivalent VSDs (S1-S4, S7-S10) and 
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pore helices (S5-S6, S11-S12). In AtTPC1 only VSD2s (S7-S10) respond to changes in voltage 
20. Three arginines on S10 of each VSD2 (equivalent to S4 in the VSD of tetrameric ion 
channels) in AtTPC1 are required for voltage-dependent activation. A homo-dimer of two TPCs 
forms the central functional channel surrounded by four pore-forming domains.  
The dependence of AtTPC1 on external and internal Ca2+ offer the opportunity to visualize the 
resting state of a voltage sensing domain of an intact channel, and the activated state and to ask 
how voltage changes are detected and relayed.  
 Lumenal Ca2+-ions suppress activation of AtTPC1 via binding to Cai2+ located in the 
active voltage sensor VSD2 with EC50 ~0.1mM. This previously enabled trapping of the resting-
state VSD2 of wild-type AtTPC1 by including 1 mM Ca2+-ions 19,20. Replacement of the Ca2+-
chelating amino acids by mutagenesis (D240N, D454N, E528Q; termed AtTPC1DDE) shifts 
voltage-dependent activation by -50 mV, such that the channel is open at 0 mV 20,28 and VSD2 in 
an activated conformation. Using AtTPC1DDE we sought to determine the structure of an 
activated state of the same intact channel where we had previously determined a resting state. 
Channel opening requires Ca2+-ion binding to Caa2+ mediated by D376 of cytoplasmic EF-
hand domain helix 3-4 loop (EF3-EF4). Removal of cytoplasmic Ca2+-ions or the mutation 
D376A (AtTPC1DA) yields permanently closed channels 29. The absolute requirement of the 
Caa2+ site for voltage-dependent activation led us to hypothesize that channel activation depends 
on communication between Caa2+ and VSD2 21. Using the D376A mutation we sought to 
determine how cytoplasmic Ca2+ evokes activation. 
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Results and Discussion 
Cryo-EM structures of AtTPC1DDE 
As a basis for understanding the voltage-dependent activation mechanism and its 
modulation by Ca2+-ions, we determined the structure of AtTPC1DDE by cryo-EM (Figure 1a and 
SI Appendix, Fig. S2, Fig. S3, Fig. S4, Table S1). We employed saposin A nanoparticles 30 to 
reconstitute AtTPC1DDE into a membrane environment, and an antibody Fab made against 
AtTPC1 (CAT06/H12) 31 to facilitate particle alignment 32 (SI Appendix, Fig. S5, Fig. S6, SI 
Discussion). 
 With a nominal resolution of 3.3 Å, the density map of AtTPC1DDE is of high quality (SI 
Appendix, Fig. S4a), allowing additional de-novo interpretation of the AtTPC1 N-terminal 
domain (NTD), the S1-S2 linker, EF3-EF4 with an intact Caa2+ site, the upper vestibule of the 
pore, and the C-terminal domain (CTD). Three ions lie in the selectivity filter, consistent with 
previously defined Ca2+/Na+-binding sites 19,20,33. Fourteen lipid molecules surround the channel 
in the lumenal leaflet with two on the cytoplasmic side (SI Appendix, Fig. S7). S1-S6 are well 
defined and remain stationary between all of the AtTPC1 structures. In AtTPC1DDE, major 
rearrangements are observed in the VSD2, the upper vestibule of pore, and EF3-EF4 on the 
cytoplasmic side, relative to AtTPC1WT (Figure 1b). The position of three residues known to be 
phosphorylated (S22, T26, and T29) are observed in previously unresolved portions of the NTD 
(SI Appendix, Fig. S4a, SI Discussion) 19.  
 The Fab binds to the EF1-EF2 loop, EF4, and S6 on the cytoplasmic side. The Fab 
binding affinity is the same with and without Ca2+ ions, in other molecular conditions tested (1 
mM EGTA, 1 µM trans-NED19, 1 µM Nicotinic Acid Adenine Dinucleotide Phosphate), and in 
three different constructs (AtTPC1WT, AtTPC1DDE, AtTPC1DA), indicating that the Fab binding 
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does not distinguish between nor is likely to influence the activation state (SI Appendix, Fig. 
S5c-d). Most of the variable domain of the Fab is visible, allowing interpretation of the 
AtTPC1DDE-Fab interface (SI Appendix, Fig. S6e-f). The constant domain of the Fab is flexible 
and not resolved to high resolution.  
 
Activation of the voltage sensor  
Lumenal Ca2+-ions inhibit AtTPC1 channel activation half maximally at ~0.1 mM 
concentration20 via binding to Cai2+ 21 between VSD2 (D454 in the S7-S8 loop, and E528 in 
S10), and the pore (D240). D454N, also named fou2 (fatty acid oxygenation up-regulated 2) 28, 
abolishes inhibition by lumenal Ca2+-ions, increasing channel open probability by shifting the 
voltage-dependent channel opening towards more hyperpolarizing potentials 28,20. Ca2+-ions do 
not inhibit AtTPC1DDE at 1 mM and up to 10 mM 33. Thus, the Cai2+ site is functionally abolished 
in AtTPC1DDE under cryo-EM conditions and thereby mimics the activated state under voltage 
and low lumenal Ca2+-ion conditions 20,33.  
While the overall resolution of AtTPC1DDE is excellent, density for S7-S10 of VSD2 is 
significantly weaker indicating conformational heterogeneity. Focused classification identified 
two states of VSD2, each with an overall resolution of 3.7 Å, but with distinct and different 
conformations of the S7-S10 domain structure (state 1 and 2) (SI Appendix, Table S1, Fig. S3, 
See Methods). We therefore conclude that these two conformations represent different functional 
states of the AtTPC1DDE channel. They suggest a model for the voltage-activation of AtTPC1, 
and a mechanism for dependence on lumenal Ca2+-ions. 
To confirm that the structural rearrangements in VSD2 were not induced by saposin A we 
determined a ~7Å reconstruction of AtTPC1WT in both detergent and in saposin A. In these the 
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overall channel architecture is comparable to the AtTPC1WT crystal structure (SI Appendix, Fig. 
S8).  
The local resolution of VSD2 (S7-S10) ranges from 4-6 Å in both states, making it 
possible to model the intermediate active state of VSD2 based on the 2.8 Å X-ray structure of 
AtTPC1WT (SI Appendix, Fig. S4b, c, See Methods under Structure Determination and 
Refinement)19. Atomic structures for states 1 and 2 were determined by real-space and B-factor 
refinement against the cryo-EM densities. Changes in solvent accessibility at the lumenal and 
cytoplasmic boundaries of VSD2 were apparent from the comparison of these new structures of 
AtTPC1 and the previous resting-state. Taking the resting state structure of AtTPC1WT as a 
reference (PDBID 5DDQ; ref. 19), transmembrane helices S7-S10 in state 1 rotate in a 
counterclockwise manner with respect to AtTPC1WT (Figure 2). The helices twist to partially 
close the cytoplasmic solvent access to the gating charges of VSD2 (Figure 3), while the lumenal 
face remains occluded. Among all helices of VSD2, the key arginine-rich S10 has the least 
movement, and R537 (R1) remains interacting with the CT (Y475), albeit the changes in S8 
conformation place R1 on the opposite horizontal face of the CT as compared with AtTPC1WT. 
S8 moves upward in the membrane plane by nearly one helical turn, thus moving the CT into 
place to interact with R1 in similar manner to AtTPC1WT. State 1 probably represents a resting-
state structure present in low lumenal (<0.1 mM) Ca2+-ion concentrations. 
 In state 2, VSD2 rotates ~20˚ clockwise in the plane of the membrane with respect to 
AtTPC1WT (Figure 2). Helices S7-S10 reorient dramatically leading to an opening of the lumenal 
face of VSD2 (Figure 3). Tilting of S10 and rotation of S8 around S10 moves the CT downward, 
placing R1 in an activated conformation. The cytoplasmic face is fully closed in state 2 while the 
 27 
lumenal side is partially open. VSD2 has effectively alternated solvent access, or electrical 
contact from the cytoplasmic to the lumenal side of the membrane.  
 Clockwise rotation was proposed to connect resting- and active-state conformations on 
the basis of comparing previous voltage-gated channel structures 13,19,34. During review of this 
manuscript, activated state structures of mouse TPC1 were determined 35. Comparing the 
activated-state mouse TPC1 to resting- and intermediate-state AtTPC1 supports the proposed 
role of VSD2 rotation during channel activation. The observation of clockwise rotation in 
multiple activated-state structures supports our conclusion that state 2 represents an intermediate-
activated state of AtTPC1. 
 These two states of VSD2 in AtTPC1 are likely to represent structures that VSD2 adopts 
in low lumenal Ca2+ during activation. The overall movement of VSD2 during activation serves 
to dilate the lumenal face of VSD2, close off the cytoplasmic leaflet to solvent, and move the CT 
below a gating charge in the membrane. This would reconnect the positive gating charges from 
the potential of the cytoplasmic side to the potential of the lumenal side upon activation, 
mediated by tilt and twisting of S7, S8, S9 around S10. This is all that is necessary to transport 
the gating charge arginine residues from cytoplasmic electrical connection, to the external 
potential. A hydrophobic sealed region between all four helices forms a thin outer insulating 
layer in the resting state, while in the activated state this becomes open to solvent and the bundle 
twists to form a hydrophobic insulating region closer to the cytoplasmic side. 
 
Drug and Lipid Binding Sites 
The high resolution map enabled refinement of a total of 14 lipids on the lumenal and 2 
on the cytoplasmic leaflet of the membrane. The lumenal lipids are modeled as the 16-carbon 
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containing palmitic acid, the predominant lipid length in soy polar lipids, whereas the 
cytoplasmic lipids are modeled as 18-carbon phosphatidic acid (PA). 12 lipids bind to the long 
axis of AtTPC1, occupying the binding site for Ned19 (SI Appendix, Fig. S7, ref. 19,21). Ned19 
binding may disrupt these structured lipids, acting as a steric block to prevent S7 and pore 
movements during gating. One lipid binds to a buried site along the short axis, sandwiched in 
between the pore domains. Based on homology to Cav channels in this region and recent 
structures of bacterial Cav channels (CavAb) bound to dihydropyridines (DHP) (amlodipine and 
nimodipine) and PPA (verapamil) inhibitors36, the short axis in transmembrane segments S6 and 
S12 is a likely site for binding of Tetrandrine, a bis-benzylisoquinoline alkaloid isolated from the 
Chinese herb Stephania tetrandra  and approved medications of the DHP class of L-type Cav 
antagonists–all TPC channel blockers.  
 The lumenal PA lipids bind along the short axis in a pocket formed by S1 of VSD1, the 
S10-S11 linker, S11, and the S8-S9 linker of VSD2. The alkyl chains make Van der Waals 
interactions, whereas the phosphoglycerol headgroup makes hydrogen bonds to the backbone of 
W492 and to the sidechain of R498 and S8-S9 of VSD2. The S8-S9 linker moves 4Å inward in 
the AtTPC1DDE structure to form the PA binding site, which would not be intact in the 
AtTPC1WT resting-state. Therefore, this lipid binding site is likely specific for AtTPC1DDE. 
Certain lipids may occupy this site during activation of AtTPC1. Polyunsaturated fatty acids 
inhibit plant TPC1 activation, but the binding site has not been determined (38). In principle, 
polyunsaturated fatty acids could mimic the observed site in the resting-state and prevent 
activation. 
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Charge transfer mechanism 
State 2 represents an intermediate activation state of VSD2 where the gating charge R1 is 
transferred across the membrane (Figure 3). In this state, the CT moves downwards, R1 moves 
slightly upwards, and overall the VSD2 bundle rotates by ~20˚ in the membrane plane with 
respect to the adjacent pore domains. In this the voltage-sensing helix S10 pivots only 2-3˚ 
inward toward the pore. Importantly, the three observed states of the VSD thus far are not related 
by rigid-body rotations. These changes in VSD2 make R1 more accessible to solvent on the 
lumenal side while charges R2 and R3 are shielded from access to the cytoplasmic side; there is 
a net transfer of charge from cytoplasmic side (in the resting state) to the outside (in the activated 
state).  
 
Pore conformational changes 
High-resolution density for the pore defines the consequences of activation by removal of 
the external Cai2+ site on VSD2 on the central channel (Figure 4a, b). As a consequence of the 
rearrangement of VSD2 the upper vestibule and the upper selectivity filter of the channel open 
along the ion permeation pathway (Figure 4c), while the lower gate remains closed (Figure 4d). 
Full channel opening may be evoked by passage of ions or an additional energy barrier, because 
electrophysiological studies show the channel is maximally open at 0 mV with removal of the 
Cai2+ site. 
 In the selectivity filter, three ions are observed (Figure 4e, f). Site 1 and 3 were occupied 
by Ca2+ mimetics, Yb3+ or Ba2+, in AtTPC1WT structures (19, 20). Site 2 was seen to be occupied 
by Na+ in the Na+-selective chimera of AtTPC1(33). Since AtTPC1DDE contains 1 mM Ca2+ and 
the channel is Ca2+-selective, these are probably hydrated Ca2+-ions (SI Appendix, Discussion). 
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Sidechain interactions from the upper vestibule of S11-S12 exclusively coordinate site 1. The 
side chains of D606 move inward to coordinate site 1 with E605 (Figure 4g). E605-Ca2+ (5.5 Å) 
and D606-Ca2+ (4.6 Å) distances are consistent with the radius of a hydrated Ca2+ ion. There are 
readjustments throughout the channel suggesting that VSD2 activation by removal of the 
lumenal Cai2+ site can indeed potentiate channel opening as observed by electrophysiology.  
 The observation of upper and lower selectivity filter and activation gate operating 
independently in our structures suggests a multi-step gating mechanism that resembles that 
proposed for TRPV1 channel activation (39). Activation of the VSDs could lead to opening of 
the selectivity filter and activation gate in two steps. First, the upper selectivity filter opens in 
response to rotational rearrangement and partial activation of the VSDs, then the lower 
selectivity filter and activation gate open when the VSD achieves maximal activation.  
 
Cytoplasmic activation by Ca2+-ions 
Full voltage-dependent activation of AtTPC1 requires ~0.3 mM cytoplasmic Ca2+ evoked 
by Ca2+-binding to the EF3-EF4 loop (20, 29). D376 in EF3 is critical; when substituted D376A 
in AtTPC1DA the channel remains closed and is no longer responsive to membrane potential (29). 
We determined the crystal structure of AtTPC1DA (Figure 5a, Table S2) to 3.5 Å resolution by 
X-ray crystallography. When compared with the AtTPC1WT crystal structure, removing the 
activating cytoplasmic Caa2+ binding site leads to higher dynamic motion (B-factors) not only in 
the EF-hand and the CTD, but also in the VSDs and upper vestibule of the pore, showing that the 
activating cytoplasmic site may act through effects on the VSDs (SI Appendix, Discussion).  
 AtTPC1DA is in a resting-state as expected. However, there is an overall effect of 
increasing the dynamical motion of VSD1, VSD2 and the pore (in the context of otherwise 
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identical overall B-factors), showing that Caa2+ has an allosteric effect in stabilization that could 
impact voltage dependence (VSDs) and conductance (the pore). The regions of increased motion 
in AtTPC1DA correspond to the regions that undergo conformational change in AtTPC1DDE, 
suggesting that there is a pathway for coupling cytoplasmic activation at Caa2+ to voltage 
dependence of activation in VSD2 and transmission to the pore.  
 The Caa2+ site in EF3 is fully formed in the cryo-EM structure of AtTPC1DDE, whereas it 
was partially occupied in AtTPC1WT and was in a more extended conformation(19, 20) (Figure 
5b). In AtTPC1DDE, EF3 alone lies 7 Å closer to the transmembrane domain and rotates 20° to 
make close contacts with EF4 (Figure 5c). The Caa2+chelating residues E374, D376, and D380 
order the EF3-EF4 loop around the activating Caa2+ site (Figure 5c). Movement of EF3 leaves the 
EF1-EF2 Ca2+ site unaltered. Therefore, EF3 is capable of undergoing large-scale movements 
that change the structure of the cytoplasmic domains and their connection to VSD2, suggesting 
that activation on the cytoplasmic side can act reciprocally through VSD2. 
The conformation of the cytoplasmic domains seen in AtTPC1DDE, probably reflects the 
predominant structure in AtTPC1WT (rather than the crystal structure) because the conformation 
of EF3 is conserved in cryo-EM structures from several conditions; detergent and saposin A 
nanoparticles of AtTPC1WT, and AtTPC1DDE, and when bound to either of two different Fab 
molecules (SI Appendix, Fig. S8c).  
 The CTD of AtTPC1 is indispensable for channel activation(40). Removal or truncation 
by 29 residues abolishes channel function. In the crystal structure of AtTPC1WT, the CTD forms 
an intramolecular complex with the EF3 via salt-bridge interaction D376-R700, leading to the 
hypothesis that the EF3-CTD complex could undergo conformational changes upon activating 
cytoplasmic Ca2+-binding (19). In the cryo-EM structures the CTD moves toward the membrane 
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vertically by 13Å to accommodate the upward movement of EF3 upon forming the cytoplasmic 
activating Caa2+ site (Figure 5b). The salt-bridge (D376-R700) that previously linked the CTD to 
EF3 in AtTPC1WT breaks to allow D376 to chelate the Caa2+ site. This can explain why only 
substitution of D376 and not the other chelating residues abolishes Ca2+-activation(29). In 
AtTPC1DDE, the CTD now forms a hydrogen bond (E366-E694) with EF3 and hydrogen bonds 
(N697-I371) via the backbone (Figure 5d). Following the interaction with EF3, and a b-turn the 
CTD to folds back on itself to form a charged zippered interaction (R696-D691, R700-Q688, 
R707-E684) between the signal poly-R and poly-E motifs of the CTD (19). The poly-E motif 
connects directly to the pore gate (Figure 5e). The role of the CTD on channel activation may be 
to stabilize the EF3 helix in both apo- and Ca2+-bound conformations to allow communication of 
EF3 movement to VSD2 and the pore gate. Upon removal of Ca2+, the CTD could adopt an 
extended conformation to reform the salt-bridge interaction D376-R700 with EF3. Without the 
CTD, EF3 may not be able to reform the Caa2+ site and would become trapped in an inactive 
state. 
 To further investigate the conformation of EF3 in solution, we performed continuous 
wave electron paramagnetic resonance (CW-EPR) experiments using spin-labeled full-length 
AtTPC1 lacking cysteines (AtTPC1cysless; See Methods) in detergent micelles. Ten positions in 
the CTD, gate, and EF-hand domains were examined by spin-probe mobility and responsiveness 
to Ca2+-ions. Labeling at a site on EF3 (R379) indicates a conformational shift to higher probe 
mobility as compared with EGTA, indicating that the probe changes environment in the presence 
of Ca2+-ions (SI Appendix, Fig. S9). Mutation of the Caa2+ site but not the Ca2+-site in EF1-EF2 
abolishes the Ca2+-dependent increase in probe mobility, suggesting that EF3/Caa2+ changes 
conformation upon increasing cytoplasmic Ca2+-ion concentrations. The data suggest that the 
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AtTPC1WT crystal structure likely represents an apo-state of EF3, whereas AtTPC1DDE represents 
a Ca2+-bound conformation present along the pathway of activation. 
 
Alternate Access Mechanism of Activation 
As the electric potential changes across a membrane, functional voltage sensors find a 
new free energy minimum. Under hyperpolarizing conditions, the favorable electrostatic free 
energy component of positive gating charges’ attraction to internal negative potential is balanced 
against a structural ‘distortion’ free energy cost. Depolarization therefore releases both of these 
components to populate a new overall equilibrium state that includes a component that regulates 
the open probability of the pore. Release of the electrostatic free energy is achieved by 
alternating access of the positively charged gating charges on S10 to solvent from the 
cytoplasmic side in the hyperpolarized resting state, to a state in which they are insulated from 
the cytoplasmic side, and become accessible to solvent from the lumenal side, without any 
necessity for vertical movement of the gating charges themselves. The structures of AtTPC1WT 
and AtTPC1DDE suggest that this ‘alternating access’ mechanism plays the key role. The 
movement of the VSD2 helices S7, S8, S9 with respect to the gating charges on S10 achieve this 
(Figure 6).  
Hence the potential gradient is focused across a thin hydrophobic region close to the 
lumenal (external) side in the resting-state, and alternately across one on the cytoplasmic side in 
the activated-state. Thus, the gating charges do not require any vertical movement across the 
bilayer as the electrically insulating region, which includes the CT and across which the voltage 
gradient is formed, moves from outside of the gating charges in the resting-state voltage sensor, 
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to the cytoplasmic side of gating charges in the activated-state. Thus, the electric component of 
free energy is released.  
 The mechanism is unique versus most previously proposed models in that S7-S9, not 
only S10 that is closest to the pore, are crucial during voltage-activation to move gating charges 
from the electric potential on one side of the membrane to the potential of the other side without 
any necessary vertical translation of S10. Even after this major driving effect, gating charge side 
chains will also readjust in context of their different environments and some vertical movement 
may find more favorable energetics in the shallow energy gradient around them.   
There is a teleologically favorable aspect to this alternate access mechanism in that it 
does not need to remove any hydrophobic residues out of the bilayer as would be required of a 
model involving large vertical movement of S10. It also does not need to rebuild the 
hydrophobic interface between S10 of the VSD and the walls of the pore with which it forms the 
primary contact that may be important in changes that alter open probability of the channel.  
Simulations of VSDs that assume a linear gradient of electric potential across the bilayer that 
changes only in slope on depolarization, but not position of start and end points across the VSD 
may not represent the true physiological state.  
 The Gibbs free energy change on moving one charge across a transmembrane potential 
difference of -70 mV is -1.6 kcal/mole. The measured gating charge transfer for activation of 
AtTPC1 is 3.9 charges(20) or -6.3 kcal/mole in free energy difference. Ca2+ binding to the 
lumenal Cai2+ site effectively stabilizes the resting-state. The EC50 for the Cai2+ site is ~0.1 mM. 
Therefore, assuming a Kd ~0.1 mM, the free energy released by removing each Cai2+ site is ~5.6 
kcal/mole per site (or ~11.2 kcal/mole per AtTPC1 channel). It is not unreasonable that this 
difference, in releasing the restraint at Cai2+, could allow the VSD to reach its active state that 
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would normally be evoked by depolarizing the transmembrane potential at low lumenal Ca2+. 
The fact that we observe intermediate states of TPC1 upon removing Cai2+ rather than the fully 
activated state suggests that the membrane voltage, or the passage of ions may contribute 
additional energy to maximize activation of VSD2 and channel open probability. 
 The mechanism suggested for AtTPC1 voltage dependent activation is the first time that 
atomic structures have been determined for intermediates on transition from resting-state to 
activated-state in an intact voltage-dependent channel. The structures also capture large-scale 
rotation of VSDs that could play a role in activation. It could be a general way in which gating 
charge can move energetically downhill in response to a change in voltage, without the energetic 
cost of removing any hydrophobic lipophilic regions out of the membrane.  
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Figure 2.1: Cryo-EM Structure of the AtTPC1DDE–saposin A–Fab complex. (A) Side 
(Left) and top-down (Right) views of cryo-EM density. The composite map is colored to 
highlight high-resolution features of TPC1 (blue, EMDB entry no. 8957), VSD2 in state 1 (cyan, 
EMDB entry no. 8958) and state 2 (pink, EMDB entry no. 8960), and the Fab variable domains 
(orange, EMDB entry no. 8956). Unsharpened density is shown at low contour (transparent 
gray). Membrane boundaries (black bars) defined by the nanodisc are marked. (B) Overlay of 
AtTPC1WT (red, PDB ID code 5DQQ), state 1 (blue), and state 2 (pink). Cai2+ and Caa2+ 
denote sites of luminal inhibition and cytoplasmic activation by Ca2+ ions. Dash lines around 
Caa2+ indicate hypothetical position in cryo-EM structure. Ca2+ ions shown as colored balls. 
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Figure 2.2: Three states of VSD2. View of VSD2 in the membrane plane from the center of the 
channel looking outward that illustrates the rotation and twisting of VSD2 helices S7, S8, S9, 
and S10. Connections to the pore domains are omitted for clarity. S10 is highlighted in each state 
with a different color than the other helices. Gating charges R1–R3 (R537, R540, and R543) and 
CT residue Y475 are shown. (Left) Resting-state AtTPC1WT (red, PDB ID code 5DQQ), 
(Center) AtTPC1DDE state 1 (blue), and (Right) AtTPC1DDE state 2 (pink). 
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Figure 2.3: Activation of the voltage sensor. Side views of a common slice perpendicular to 
the membrane surface of VSD2 in AtTPC1WT resting state (red, PDB ID code 5DQQ) and 
AtTPC1DDE state 1 (blue) and state 2 (pink). S10 shown with gating charges R1–R3. The CT 
Cα position (black ball) is marked. Based on a structural alignment with respect to the pore 
helices S6–S7 of each structure. 
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Figure 2.4: Ion permeation pathway. (A and B) Orthogonal side views through pore helices 
(A) S5–S6 (pore 1) and (B) S11–S12 (pore 2) of the channel homodimer overlaid with high-
resolution cryo-EM density (gray mesh). (C) HOLE plot of pore radii along central channel 
coordinate of AtTPC1DDE (red) and AtTPC1WT (blue). (D) Top-down view through central 
pore. Gate residues Y305, L673, and F676 are shown. (E–G) Side views through the selectivity 
filter in (E) pore 1, (F) pore 2, and (G) an overlay of pore 2 of AtTPC1DDE (blue) and 
AtTPC1WT (pink). (Upper) E605 and D606 and (Lower) S265, T263, T264, V628, M629, and 
N631 selectivity filter residues are shown. Density for lipids (SI Appendix, Fig. S7) and ions is 
omitted for clarity. 
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Figure 2.5: Dynamics of cytoplasmic domains. (A) Overlay of (Left) AtTPC1WT and (Right) 
AtTPC1DA crystal structures colored by B-factor value (100–450 Å2) (see Methods and SI 
Appendix, Supplementary Discussion). (B) Side views of AtTPC1WT (red) and AtTPC1DDE 
(blue). (C) Views from (Top Left) side and (Top Right) bottom of EF3 for overlaid AtTPC1DDE 
(blue) and AtTPC1WT crystal structures (red, PDB ID code 5DQQ). CTD interactions are 
omitted for clarity. Ca2+-ion binding sites in (Bottom Right) EF1–EF2 and (Bottom Left) EF3–
EF4. (D) View of EF3-CTD and EF3-EF4 interactions and connection to VSD2. (E) Structure of 
the CTD in AtTPC1DDE and a possible coupling pathway to the pore gate and Caa2+. Dashed 
lines indicate the hypothetical Caa2+ ion position.  
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Figure 2.6: Mechanism of TPC1 channel activation. Schematic summarizing the 
conformations of VSD2, EF3, CTD, and selectivity filter (SF) observed in crystal and cryo-EM 
structures under high and low effective luminal Ca2+-ion concentrations. A potential model for 
coupling between luminal inhibition Cai2+, cytoplasmic activation Caa2+, voltage sensing, and 
channel gating is shown. Helices and ions that move between the AtTPC1WT resting state (red), 
AtTPC1DDE state 1 (cyan), AtTPC1DDE state 2 (pink), and hypothetical activated-open state 
(purple) are colored. Ca2+ ions are shown as green balls. Gating charges that change position 
with respect to the CT (dashed line) between states are colored red. 
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Table S1. Cryo-EM data collection and refinement statistics 
Data collectiona 
Voltage (kV) 300    
Pixel size (Å) 1.2156    
Defocus range (μm) -0.8 – -2.0    
Total electron dose (e-/A2) 60    
Exposure time (s) 12    
Number of frames/image 60    
Number of images 3,408    
Image processinga,b 
Map High-res State 1 State 2 Fab-bound 
Autopicked particles 996,035    
Particles post 2D 409,531    
Final particle number 224,577 44,353 67,308 224,577 
Resolution (unmasked, Å) 3.7 4.2  4.3  4.0 
Resolution (masked, Å) 3.3 3.7  3.7  3.7 
Sharpening B-factor (Å2) -117 -95 -86 -104 
Refinementa,c 
Number of atoms 8913 10682 10697 11641 
R.m.s. deviations 
    Bond lengths (Å) 
    Bond angles (o) 
0.017 
1.481 
0.014 
1.305 
0.009 
1.090 
0.018 
1.679 
Ramachandran 
    Favored (%) 
    Allowed (%) 
    Outlier (%) 
91.49 
8.41 
0.10 
91.59 
8.25 
0.16 
92.95 
6.89 
0.16 
88.32 
11.39 
0.29 
Mean B-factor (Å2)d 101.80 142.71 201.66 100.50 
Molprobity Clashscoree 5.51 7.96 7.47 8.36 
EMRinger scoref 3.94 1.63 1.42 2.92 
PDB IDg 6E1M 6E1N 6E1P 6E1K 
EMDB IDg 8957 8958 8960 8956 
 
a Data collection and processing detailed in Methods. 
bImage processing schematic in Extended Data Fig. 4. 
cReal-space refinement in PHENIX as outlined in Methods. 
dAs implemented in PHENIX, number of clashes per 1000 atoms. 
eCalculated from real-space refinement in PHENIX. 
fCalculated using EMRinger in PHENIX. 
gDeposition codes for coordinates and maps deposited to the Protein Data Bank and Electron Microscopy Data Bank. 
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Table S2. X-ray Data Collection and Refinement Statistics for AtTPC1DA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aUncorrected native data 
bValues in parenthesis are for highest resolution shell. 
cPercentage of correlation between intensities from random half-datasets, as calculated in XDS. 
dAnisotropy as determined by Diffraction Anisotropy Server. 
eAnisotropy-corrected data used for refinement with sharpening B-factor of -142.05 Å2. 
f5% of reflections were omitted from refinement for the calculation of Rfree. 
gDeposition codes for coordinates and maps deposited to the Protein Data Bank and Electron  
 Microscopy Data Bank. 
 
  
Data Collection AtTPC1DAa 
Beamline ALS 8.3.1 
ALS 5.0.2 
SSRL 12-2 
Space Group C2221 
Cell Dimensions a=88.47, b=154.42, 
c=218.45, α=β=γ=90 
Wavelength (Å) 1.000 
Resolutionb 30-3.5(4-3.5) 
Number of reflections 19231 
Completeness (%) 99.7(99.8) 
Multiplicity 13.3(13.6) 
I/σI 8(0.93) 
CC1/2c 100(57.7) 
Rmeas (%) 23.6(362.2) 
Anisotropy  
(a, b, c)d 
3.5 x 6.0 x 4.5Å 
Refinement  
Resolution (Å) 3.5 x 6.0 x 4.5Åe 
No. reflections 8954 
Rwork/ Rfree 0.3184/0.3519f 
No. atoms 5092 
    Protein 5054 
    Ligand/ion 38 
B-factor 114.26 
R.M.S. deviations  
    Bond lengths (Å)  0.003 
    Bond angles (º) 0.687 
Ramachandran (%)  
Favored 93.09 
Allowed 6.25 
Outliers 0.66 
PDB IDg 6CX0 
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Methods 
Protein Production 
AtTPC1. X-ray and cryo-EM trials used AtTPC1 with deletion of residues 2-11(19). Antibody 
generation employed full-length AtTPC1. AtTPC1 constructs were expressed and purified by 
nickel affinity chromatography (NiNTA), thrombin cleavage, and size exclusion, as described 
previously(19). For reconstitution into saposin A lipoprotein nanoparticles and MSP nanodiscs, 
the size exclusion step was omitted after NiNTA, but performed after reconstitution. To 
introduce single cysteine labels for CW-EPR, a cysteine-less variant of AtTPC1, AtTPC1cysless, 
was constructed to replace all native cysteines with serines (C93S, C101S, C159S, C347S, 
C392S, C574S, C577S, C580S, C687S, C728S). Cysteine substitutions for EPR spectroscopy 
were purified in the presence of 1mM TCEP during solubilization and binding to Nickel beads, 
but then removed during wash and elution steps to prevent interference with MTSL-labeling. 
AtTPC1cysless has identical biochemical behavior to wild-type AtTPC1. 
Saposin A. Human saposin A (plasmid was a kind gift from J. Frauenfeld) was expressed and 
purified from E. coli Rosetta-gami 2(DE3) cells essentially as described(30). Several colonies 
from transformed cells were used to inoculate overnight 300 mL LB cultures containing 25 
µg/mL chloramphenicol, 10 µg/mL tetracycline, and 15 µg/mL kanamycin at 37 ˚C. Overnight 
cultures were used to seed 6 L of Terrific Broth, grown to an absorbance value at 600 nm of 1. 
The temperature was adjusted to 20 ˚C 30 minutes prior to induction by 0.7 mM IPTG for 15 
hours at 20 ˚C. Cells were harvested by centrifugation at 4,000x g for 10 minutes and 
resuspended in 200 mL 50 mM tris pH 7.4, 150 mM NaCl (Lysis Buffer) and frozen at -80 ˚C 
before further use. Bacterial pellets were lysed in the presence of 1 mM phenylmethylsulfonyl 
fluoride (PMSF) by sonication for 5 minutes, then clarified by centrifugation at 26,000x g for 20 
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minutes. The supernatant was then incubated at 70 ˚C for 10 minutes followed by centrifugation 
at 26,000x g for 20 minutes to remove contaminant proteins. Imidazole pH 7.4 was then added to 
20 mM and passed through two HisTrap FF crude 5mL columns equilibrated in Lysis Buffer 
with 20 mM Imidazole pH 7.4 using a peristaltic pump. Following 50 mL washes with Lysis 
Buffer with 20 mM Imidazole pH 7.4 and Lysis Buffer with 35 mM Imidazole pH 7.4, pure 
human saposin A was eluted in 25 mL Lysis Buffer with 400 mM Imidazole pH 7.4 in 1.5 mL 
fractions. Fractions containing human saposin A were dialyzed against 1 L of Lysis Buffer with 
4 mg of Tobacco Etch Virus (TEV) protease. The following morning an additional 2 mg of TEV 
was added with an exchange of the dialysis buffer and dialyzed at room temperature for 3 hours. 
Uncleaved saposin A and free TEV were removed by passing the protein through a single 
HisTrap FF crude 5 mL column equilibrated in Lysis Buffer with 20 mM Imidazole pH 7.4 and 
washed with 30 mL of Lysis Buffer with 20 mM Imidazole pH 7.4. The flow-through and wash 
fractions were pooled and concentrated in 5 kDa molecular weight cutoff concentrators and 
serially injected in 20 mg aliquots over TSKgel G3000SW 7 mm x 60 cm or Superdex S200 
10/300 columns equilibrated in Lysis Buffer with 1 mM CaCl2. High and low molecular weight 
peaks were observed during size exclusion. The low molecular weight, most consistent with the 
size of the saposin A monomers and dimers, was concentrated to 2 mg/mL for use in 
reconstitution of AtTPC1 and frozen at -80 ˚C. Final yields of human saposin A were 5-10 
milligrams of human saposin A per liter of culture. 
Membrane scaffold protein. Plasmid harboring His-tagged E3D1 variant of membrane scaffold 
protein (MSP) of the nanodiscs was obtained from Addgene (#20066). MSP was expressed, 
purified and cleaved with TEV protease as described(41) with minor modifications. Colonies of 
transformed BL21 (DE3) Gold cells (Stratagene) were used to inoculate overnight 30 mL LB 
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cultures containing 30 μg/mL kanamycin. Overnight cultures were used to inoculate 2 L of Terrific 
Broth, grown at 37 ˚C until OD600 of 1.3 and then induced with 1 mM IPTG for 3 hrs. Cultures 
were harvested by centrifugation at 4,000x g for 10 minutes, resuspended in 50 mM Tris pH 8.0, 
300 mM NaCl (MSP Lysis Buffer) supplemented with 1% Triton X-100, protease inhibitor tablet 
and 1 mM PMSF. Microtip sonicator (Branson) was used to lyse the cells for 3 cycles at 1s on, 1 
off and at 60% amplitude for 3 minutes each. For each 1L culture 1 mL of NiNTA resin 
equilibrated with MSP Lysis Buffer was used in batch-binding for 1 hour at 4 ˚C. Resin was then 
washed with MSP Lysis Buffer supplemented with: 1) 1% Triton X-100 - 10 column volumes 
(CVs), 2) 50 mM sodium cholate, 20 mM imidazole – 5 CVs, 3) 50 mM imidazole – 7 CVs. MSP 
was eluted with 4 CVs of MSP Lysis Buffer supplemented with 400 mM imidazole. TEV cleavage 
was performed overnight in dialysis against 4 L of 50 mM Hepes pH 7.5 and 200 mM NaCl. Uncut 
protein was removed with subtractive step on NiNTA resin and cleaved MSP was concentrated to 
5 mg/mL using Millipore concentrators with 10 kDa molecular weight cutoff and frozen in aliquots 
at -80 ˚C. Typical yield of MSP E3D1 from 1 L culture was 15 mg. 
Antibodies. Monoclonal antibodies were expressed and purified from hybridoma culture 
supernatants using standard methods in the Monoclonal Antibody Core Facility at OHSU (Dan 
Cawley). 4B8 Fab fragment was generated by papain digestion 1/20 Papain:4B8 (w/w) at 30 ˚C 
for 1 hour in the presence of 5 mM L-cysteine and quenched with 20 mM iodoacetamide. Full-
length IgG and Fc regions were removed via protein A chromatography and the flow-through 
containing 4B8 Fab was concentrated and purified by TSK3000/Superdex200 size exclusion 
chromatography in 20 mM Hepes pH 7.4, 0.2M NaCl, 5% Glycerol. 
Antibody fragments (Fabs) generated by phage display were expressed and purified 
essentially as described(42) from constructs subcloned into the expression vectors pRH2.2 or 
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pSFV4 (gift from S. Sidhu). DNA was transformed into BL21-Gold(DE3) (Agilent) and used 
directly to set up 15 mL overnight starter cultures in 2xYT media supplemented with 50 ug/mL 
ampicillin. Cultures were then inoculated into 1 L of 2xYT media, grown until OD600 of ~0.8-
1.0, induced with 1 mM IPTG for 4 hours at 37 °C. Cells were harvested by centrifugation and 
disrupted in lysis buffer containing 20 mM sodium phosphate dibasic pH 7.4, 500 mM NaCl, 1 
mM PMSF, and 2 mM DNase, using sonicator (Branson). Lysate was heated to 55 °C for 30 
minutes, cleared by centrifugation and incubated with 1 mL of MabSelect ProteinA resin (GE 
Healthcare) in batch for 1 hour at 4 °C. Resin was washed with 15 column volumes of 20 mM 
sodium phosphate dibasic pH 7.4, 500 mM NaCl and then eluted with 10 ml 0.1 M acetic acid 
into tubes containing 1 mL of 1 M Hepes pH 7.5 to immediately neutralize elutions containing 
Fab fragments. Fabs were then dialyzed against 4 L of 50 mM HEPES pH 7.5 and 200 mM 
NaCl, concentrated with Millipore concentrators with 30 kDa molecular weight cutoff and stored 
in aliquots at -80 ˚C. Typical yield from 1 L culture varied depending on Fab fragment and was 
between 0.5 – 3 mg. For cryo-EM studies Fab CAT06 was modified with H12 elbow variant as 
described previously(43), resulting in the CAT06/H12 antibody fragment. Briefly, the H12 
elbow variant exchanges heavy chain residues (112)SSASTK(117) (numbering according to 
Kabat (44)) to (112)FNQI-K(117) with one position deleted from the sequence.  
Saposin A and Nanodisc Reconstitution 
Lipids. All lipids were prepared from thin films. Lipids were dissolved in chloroform, aliquoted 
into glass vials, dried under nitrogen, and stored at -20 ˚C dry. Unless otherwise noted, 
resuspending lipids was accomplished by adding buffer with or without detergent and sonicating 
10-30 minutes until clear. 
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Saposin A nanoparticles. Saposin A nanoparticles containing AtTPC1 were formed by mixing 
AtTPC1 alone or AtTPC1-Cat06/H12 Fab complexes with soy polar lipids and saposin A in a 
1:8:5-10 ratio by mass. A typical preparation consisted of 2.4 mg (8 mg/mL) of NiNTA purified 
AtTPC1 incubated with 2.4 mg (9 mg/mL) of protein A purified CAT06/H12 (adjusted to 0.05% 
DDM, 1 mM CaCl2), incubated at room temperature for 5-10 minutes. AtTPC1-Cat06/H12 Fab 
complexes were then mixed with 4.8 mL of 5 mg/mL soy polar lipids (diluted from a 25 mg/mL 
stock in 1% DDM) dissolved in Size Exclusion Buffer (20 mM Hepes pH 7.3, 0.2 M NaCl, 5% 
Glycerol, 1 mM CaCl2, 0.05% DDM) and incubated at room temperature for 30 minutes. Then 
9.6 mL (2 mg/mL) saposin A was added, incubated 1 hour at room temperature, then diluted to 
40 mL with Size Exclusion Buffer. Detergent was removed by adding 1 g of activated, washed, 
Bio-Beads SM2 (BIO-RAD) resin overnight at 4˚C. Bio-Beads were activated by incubation in 
methanol and successively washed with copious amounts of water. The following morning, 
beads were removed by filtration through 5 µm syringe filter. 0.5 molar equivalent of Fab 
CAT06/H12 was added, incubated 30 minutes at 4 ˚C, then concentrated to ~0.3 mL in a 100 
kDa MWCO concentrator, and filtered prior to injection on a TSK4000 or Superose 6 column 
equilibrated in Nanodisc Size Exclusion Buffer (20 mM Hepes pH 7.3, 0.2 M NaCl, 1 mM 
CaCl2). A single fraction was selected for cryo-EM analysis by screening for homogeneous 
particles by negative-stain EM (SI Appendix, Fig. S6b-d). Cryo-EM grids were frozen following 
ultracentrifugation at 100,000x g (TLA-55) for 5 minutes at 4 ˚C without further concentration. 
AtTPC1-CAT06/H12-saposin A complexes typically eluted from size exclusion at 0.5-1 mg/mL. 
16 lipids are observed bound to AtTPC1DDE (SI Appendix, Fig. S7). 
MSP nanodiscs. Reconstitution of AtTPC1 into E3D1 nanodiscs was performed using standard 
protocols(45). For the purpose of antibody generation by phage display, full-length AtTPC1WT 
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was reconstituted into nanodiscs using biotinylated version of MSP E3D1, and size exclusion 
fractions corresponding to AtTPC1 in biotinylated nanodiscs were used without the removal of 
empty nanodiscs. Final mixed lipid-detergent micelles used in reconstitution contained 10 mM 
soy polar extract, 1 mM CHS, and 30 mM DDM. Nanodisc assembly mix was prepared using 
purified TPC1, mixed micelles and MSP at 2:10:1000 ratio. All components were mixed together 
in Nanodisc Size Exclusion Buffer and incubated on ice for 1 hour. Next, 400-500 mg activated 
Bio-Beads were added per each ml of assembly mix, and the reconstitution reaction was left 
shaking overnight at 4°C. As a control, empty nanodiscs were prepared using the same 
phospholipids. All nanodisc samples for phage display experiments were concentrated, 
supplemented with 5% w/v sucrose, aliquoted, flash-frozen in liquid nitrogen, and kept at -80°C.  
Proteoliposomes. Proteoliposomes of full-length wild-type AtTPC1 were formed by 
resuspending 20mg of soy polar lipids dried from chloroform resuspended in 4 mL Nanodisc 
Size Exclusion Buffer, subjected to 10x alternating liquid Nitrogen and warm water bath freeze-
thaw cycles, then sonicated for 10 min. The opaque mixture was then passed through an Avestin 
hand extruder with a 400 nm pore size 10x until mildly translucent. Vesicles were disrupted by 
addition of 69.8 µL 10% DDM added (4 mM final), 12.1 µL 2% CHS in 10% DDM added (0.1 
mM final), and 1 mM CaCl2, and stirred 30 minutes at room temperature. 2 mg of AtTPC1 was 
added to disrupted liposomes (1:10 protein:lipid ratio) and stirred for 1 hour at room temperature 
using a magnetic “flea” stir bar. To form proteoliposomes, methanol washed Bio-Beads were 
added in increments of 300 mg, 300 mg, 500 mg, and 1 g in 1-hour intervals at room 
temperature. The last incubation was done at 4 ˚C overnight. The following morning the samples 
were centrifuged at 100,000x g for 1 hour in a table-top ultracentrifuge (TLA-55). The 
proteoliposome pellet was resuspended in in 0.4 mL of Nanodisc Size Exclusion Buffer. The 
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concentration was estimated by gel and frozen in liquid Nitrogen and stored at -80 ˚C. Empty 
liposomes were made in a similar fashion by substituting AtTPC1 protein with Size Exclusion 
Buffer. 
Antibody Generation 
Hybridoma. Hybridoma cell lines were generated by standard methods at OHSU by Daniel 
Cawley. Briefly, four Balb/c mice were injected with 25 µg of AtTPC1 proteoliposomes at 0 and 
14 days. On day 26, serum was prepared and tested for antibody titer in ELISA. The mice with 
the highest titers were used to derive hybridomas. The two best responding mice were injected 
on day 45-55 with 10 µg Ag as a final boost. 4 days later, spleen cells are fused with P3X mouse 
myeloma cells. Hybridomas were assayed 12 days later in ELISA. All candidate cell lines were 
expanded and given a secondary ELISA screen 12-14 days later. All antigen specific antibodies 
were made available as culture supernates for screening. All candidate cell lines are frozen in 
liquid nitrogen. 14 hybridoma antibodies were identified that specifically bind to immobilized 
biotinylated AtTPC1 in DDM detergent by ELISA. To select for antibodies that recognize 3D 
structural epitopes a counter-selection against antibodies that bind linear epitopes on denatured 
protein in 8M Urea was performed, yielding 5 antibodies that bind only under native conditions 
by ELISA. Selection of high-affinity antibodies that were capable of complex formation was 
conducted by fluorescence size exclusion chromatography(46) (FSEC) using FITC-labeled 
AtTPC1 and hybridoma supernatants containing 10-50 µg/mL whole IgG. FSEC samples were 
prepared by mixing 1µg FITC-Labeled AtTPC1 with 0.4 mL hybridoma supernatants 
(supplemented with components to make Size exclusion buffer +0.03 mg/mL Soy Polar Lipids) 
in a total volume of 490 µL of Size exclusion buffer. Samples were incubated at 25 ˚C for 1 hour 
or 4 ˚C for 4-5 hours and injected on a Superose 6 column, 0.4 mL/min, equilibrated in Size 
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exclusion buffer at 4 ˚C, using an autosampler and inline fluorescence detector set at 
excitation=495 nm and emission=518 nm. The fluorescence detector (Shimadzu RF-10AXL) 
was calibrated before use by injecting varying amounts of FITC-AtTPC1 (0.1 ng-1 µg) with 
known labelling efficiency. 
Phage Display. To generate Fabs, the efficiency of biotinylation of AtTPC1WT-E3D1 nanodiscs 
was evaluated by pull-down on streptavidin-coated magnetic beads (Promega). Library sorting 
steps were performed using Fab Library E (DNA kindly provided by S. Koide(47)) based on 
previous protocols(31, 48). Six independent phage library sorting experiments were performed 
against biotinylated AtTPC1WT -E3D1 nanodiscs in 2 buffers containing 20 mM Hepes pH 7.3, 
200 mM NaCl, 5% glycerol, 1% BSA, and either 1 mM CaCl2 or 1 mM EGTA. Additionally, for 
each CaCl2 or EGTA condition, sorting was carried out in the presence of following ligands: 
either 1 μM NAADP, 1 μM trans-NED19, or no ligand control to maximize the number of 
multiple states of TPC1 channel during sorting (Sorting Buffer). Total of five rounds of phage 
library sorting were performed for each sample with decreasing concentration of immobilized 
biotinylated TPC1-E3D1 nanodiscs between subsequent rounds in following order 1000 nM, 600 
nM, 200 nM, 200 nM and 100 nM. Round 1 of sorting was performed manually using nanodisc 
bound to streptavidin-coated magnetic beads, and upon washing with respective Sorting Buffer, 
whole beads were used to infect log phase E. coli XL-1 strain (Stratagene) in the 2xYT media 
(Fisher) supplemented with 50 µg/ml ampicillin and 109 pfu/ml of KO7 helper phage (NEB) 
overnight at 37 °C and 280 rpm to amplify the phage particles. The amplified phage particles 
after round 1 were used as an input for four additional rounds of library sorting performed semi-
automatically with a KingFisher magnetic bead handler (Thermo) according to described 
protocols(49). Starting from round 2, in every step except elution, the buffer was supplemented 
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with 10-fold molar excess of non-biotinylated empty E3D1 nanodiscs to counter-select for MSP-
, lipid-, and non-specific phage particles. Finally, in each of rounds 2-5, phage particles were 
eluted from magnetic beads by 15-minutes incubation with 1% Fos-Choline-12 in respective 
Sorting Buffer. 
Initial validation of selection clones was performed by single point direct phage ELISA 
using clones from round 3, 4 and 5. Amplified phage particles at 10-fold dilution were assayed 
against 50 nM biotinylated nanodiscs (either empty or with AtTPC1) using HRP-conjugated anti-
M13 monoclonal antibody (GE Healthcare, #27-9421-01). Assays were performed in respective 
Sorting Buffer supplemented with 2% BSA. Each Fab clone with A450 signal above 0.2 (four 
times the average background level of the assay) was sequenced; unique Fabs were sub-cloned 
into pSVF4 or pRH2.2 vectors (kind gift of S. Sidhu), and purified as described above. In total 
16 unique Fab sequences were obtained from total of 192 single colonies screened; 9 Fabs from 
library sorting with CaCl2 and 7 Fabs from library sorting with EGTA. 
Cryo-EM Structure Determination 
Sample Preparation. Samples were analyzed by negative-stain EM to determine suitability for 
cryo-EM. To prepare grids, 3 μl of sample at 10–50 μg ml-1 was applied to a glow discharged 
continuous carbon grid, which was then treated with 0.75% (w/v) uranyl formate. Grids were 
imaged on an FEI Tecnai T12 microscope operated at 120kV at a nominal magnification of 
52,000× using an UltraScan 4000 camera (Gatan) or an FEI Tecnai T20 microscope operated at 
200kV and at a nominal magnification of 80,000× using a TemCam-F816 8k × 8k CMOS 
camera (TVIPS) camera, corresponding to pixel sizes of 2.21 Å and 0.95 Å, respectively, on the 
specimen.  
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 Grids for cryo-EM were prepared with FEI Mark IV vitrobot. Quantafoil R1.2/1.3 400 
mesh holey carbon grids (EMS) were glow-discharged for 30 s. Then 2.5 μl protein sample 
at a concentration of 0.6-1.5 mg ml−1 was applied onto the carbon face of the grids. The grids 
were blotted with Whatman#1 filter paper for 2-4 s at 100% humidity and plunge 
frozen in liquid ethane. The grids were loaded onto a 300kV Polara (FEI) with a K2 Summit 
direct electron detector (Gatan). Data were collected at nominal magnification of 31,000×, 
corresponding to a physical pixel size of 1.2156 Å (0.6078 Å super resolution pixel size) on the 
specimen with a dose rate of 7.6 electrons per physical pixel per second. Images were recorded 
with SerialEM in super-resolution counting mode and a defocus range of −0.8 to −2.0 μm. A 
total exposure of 12 s was used, with 0.2 s subframes (60 total frames) to give a total dose 
of 60 electrons per Å2 (1.35 electrons per Å2 per subframe). Data for AtTPC1WT in saposin A 
was also collected at the Janelia Cryo-EM facility FEI Titan Krios microscope operated at 300kV 
with a K2 camera with a physical pixel size of 1.02 Å.  
Image Processing. For negative-stain data, GCTF(50), Gautomatch (Kai Zhang, url: 
https://www.mrc-lmb.cam.ac.uk/kzhang/), and RELION-2(51) were used for CTF estimation, 
particle picking, and 2D classification, respectively. For cryo-EM data, dose-fractionated super-
resolution image stacks were drift corrected and binned 2×2 by Fourier cropping using 
MotionCor2(52) (after discarding the first frame). CTF determination and particle picking was 
performed on motion-corrected sums without dose-weighting using GCTF and Gautomatch. To 
generate particle picking templates and initial models a Gaussian reference was used to pick 
particles and 2D classification was performed in RELION-2 followed by ab-initio reconstruction 
in cryoSPARC. Particles were then picked using six 2D classes as templates. 2D classification, 
3D classification and refinement procedures were carried out using and RELION-2 and 
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cryoSPARC(53) (SI Appendix, Fig. S3). After 3D classification the reconstruction was filtered 
to 30 Å resolution and used as an initial reference model for 3D refinement in cryoSPARC v2 
using the beta version of non-uniform refinement yielding a reconstruction with a gold-standard 
Fourier shell correlation of 3.5 Å with a 0.143 cutoff criterion. The map from cryoSPARC was 
used for modeling the Fab variable domain. The final 3.3 Å high-resolution reconstruction was 
performed in RELION-2 using 3D auto-refinement by masking out the saposin A membrane belt 
and the Fab using a mask created from a 30 Å low-pass filtered model of AtTPC1WT. Local 
resolution estimates were performed using RELION-2. The final maps were sharpened in 
RELION-2 using a B-factor of -104 and -117 Å2 for the TPC1-Fab-saposin and TPC1-only 
reconstructions, respectively. 
 State 1 and 2 were identified by focused classification of VSD2 without image alignment 
using the angles determined from the high-resolution reconstruction (SI Appendix, Fig. S3). 
Focused classification benefitted from applying C2 symmetry. After 3D classification each 
particle set was refined in RELION-2 with global angular searches using a 30Å low pass filtered 
reconstruction of the combined dataset. The maps for state 1 and 2 extend to 3.7 Å as determined 
by the gold-standard FSC. These maps were used to build atomic models for VSD2 with local 
resolution in this region ranging from 4-6 Å as estimated by RELION-2 (Table S1). The final 
maps were sharpened in RELION-2 using a B-factor of -95 and -86 Å2 for the state and state 2 
reconstructions, respectively. 
Structure Determination and Refinement. The entire structure of AtTPC1DDE excluding VSD2 
was built into the highest resolution map (High-res; Table S1) manually after initial real-space 
flexible fitting and refinement of the AtTPC1WT structure into the map using Rosetta (54) with 
the electron scattering table. Manual fitting in COOT(55), followed by real-space coordinate and 
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B-factor/atomic displacement factor refinement in PHENIX(56) were used in de novo building of 
the NTD, EF-hand, CTD, Ca2+-ions, lipid molecules (palmitic acid and phosphatidic acid), and 
the Fab-AtTPC1DDE interface. This map was calculated with a mask around TPC1, excluding the 
Fab. A structure of the Fab-complex (Fab-bound; Table S1) was determined from the same 
dataset by extending the mask to include the Fab variable domains (VH and VL). The Fab was 
built using a homologous structure of a Fab from the same library (PDB 3PGF) with the variable 
CDR loops deleted. 
 Building of the state 1 (State 1; Table S1)was accomplished by rigid body alignment of 
the AtTPC1WT structure to the cryo-EM map using CHIMERA (57) followed by flexible fitting 
and refinement in Rosetta, and extensive manual fitting in COOT. State 2 (State 2; Table S1) was 
built by first rotating VSD2 of AtTPC1WT to place S10. Movement of S7-S9 around the S10 axis 
was done manually in real-space. Gating charges R1-R3 were placed in favored rotamer 
positions using the rotamer library in COOT and PHENIX, while applying the additional 
restraint that R1-R3 must contact solvent, a polar side chain, or counter charge in the membrane. 
One position satisfied these criteria for each gating charge. 
 Model validation employed MolProbity(58) and EMRinger(59). Low resolution maps of 
AtTPC1WT-4B8 were interpreted by flexible fitting of the AtTPC1WT crystal structure and a 
homology model of 4B8 in real-space using Rosetta. 
Crystal Structure Determination. AtTPC1 D376A (AtTPC1DA) crystals were obtained in the 
presence of CaCl2, CHS, soy polar lipids, and 1mM trans-NED19 (NED19), using HiLiDe(60) as 
described previously(19). Average diffraction was 4 Å, with 10% diffracting to 3.5-3.7 Å 
resolution, the best being 3.5 Å. Anisotropic resolution was determined using the CCP4 program 
Truncate(61) and the UCLA Anisotropy Server(62). Crystals were partially dehydrated by 
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incubation with additional 15% (v/v) of polyethylene glycol 300 prior to freezing in liquid 
nitrogen. 
 X-ray diffraction datasets were collected at the Advanced Light Source (ALS) Beamlines 
8.3.1 and 5.0.2 and at Stanford Synchrotron Radiation Lightsource (SSRL) Beamline 12-2. Data 
were reduced using XDS(63). The best native dataset extends to overall resolution 3.5 x 6.0 x 4.5 
Å (ref.(62)). Phases were calculated by molecular replacement using PHASER(64) and AtTPC1 
wild-type (PDBID 5DQQ) as a search model. Structure interpretation was using COOT(55), with 
refinement in PHENIX(56). The structure of AtTPC1DA was refined to 3.5 Å resolution with 
final Rwork/Rfree of 31.84 % and 35.19%. A sharpening B-factor of  -142.05 Å2 was used for 
refinement, as described previously(19). Analysis by Molprobity shows Ramachandran 
geometries of 93.09%, 6.25%, and 0.66% for favored, allowed, and outliers. The structure 
contains 11.31% rotamer outliers. For comparison of B-factors between AtTPC1WT (mean 
Wilson B-factor 108 Å2; PDB ID 5DQQ)(19) and AtTPC1DA (mean Wilson B-factor 109.86 Å2) 
structures, B-factors were first scaled by adding the difference in mean wilson B-factor (1.86 Å2) 
to the mean wilson B-factor of the wild-type AtTPC1 crystal structure (PDBID 5DQQ)(19). 
Sample Preparation for CW-EPR. Concentrated (7-12 mg/mL) NiNTA-purified AtTPC1cysless 
mutations were incubated with 10-fold molar excess MTSL (MTSL; Toronto Research 
Chemicals, Inc) dissolved at 10 mg/mL in DMSO for 2 hours at room temperature. The samples 
were then split in half and treated with either 1mM CaCl2 or 5mM EGTA pH 7.4 prior to 
filtration and purification by size exclusion chromatography in 1mM CaCl2 or 5mM EGTA pH 
7.4, respectively. AtTPC1cysless has identical biochemical behavior to AtTPC1WT and maintains 
structural integrity as evidenced by negative-stain EM analysis. Fractions containing labeled 
AtTPC1cysless were pooled and concentrated to 5 mg/mL for EPR measurements. 
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EPR Data Collection. For continuous wave (CW) EPR experiments, X-band spectra were 
collected on a Varian E-102 Century series spectrometer fitted with a loop-gap resonator 
(Medical Advances, Milwaukee, WI). Samples (10 uL) were contained in a 0.64/0.80 mm 
(i.d./o.d.) quartz capillary (Vitrocom, Mountain Lakes, NJ) and spectra were recorded at room 
temperature over 100 G with an incident microwave power of 2 mW, modulation amplitude of 1 
G, and modulation frequency of 100 kHz; typical total scan times were 5 minutes. CW spectra 
were normalized and corrected for minute deviations in baseline prior to comparison and 
analysis. All data were plotted using Origin 6 after normalizing the area under integrated CW 
spectrum. 
Cryo-EM structural data of AtTPC1DDE has been deposited to the Protein Data Bank under 
accession codes 6E1K, 6E1M, 6E1N, 6E1P and the Electron Microscopy Data Bank under 
accession codes 8956, 8957, 8958, 8960. X-ray structural data of AtTPC1DA has been deposited 
to the Protein Data Bank under accession code 6CX0. Correspondence and requests for materials 
should be addressed to R.M.S (stroud@msg.ucsf.edu) and Y.C. (ycheng@ucsf.edu). 
  
 58 
References 
1.  B. Hille, Ion Channels of Excitable Membranes, Third Edition, 3rd Edition edition (Sinauer 
Associates, 2001). 
2.  X. Tao, A. Lee, W. Limapichat, D. A. Dougherty, R. MacKinnon, A Gating Charge Transfer 
Center in Voltage Sensors. Science 328, 67–73 (2010). 
3.  S. K. Aggarwal, R. MacKinnon, Contribution of the S4 Segment to Gating Charge in the 
Shaker K+ Channel. Neuron 16, 1169–1177 (1996). 
4.  S.-A. Seoh, D. Sigg, D. M. Papazian, F. Bezanilla, Voltage-Sensing Residues in the S2 and S4 
Segments of the Shaker K+ Channel. Neuron 16, 1159–1167 (1996). 
5.  W. A. Catterall, Molecular Properties of Voltage-Sensitive Sodium Channels. Annu. Rev. 
Biochem. 55, 953–985 (1986). 
6.  H. R. Guy, P. Seetharamulu, Molecular model of the action potential sodium channel. Proc. 
Natl. Acad. Sci. U. S. A. 83, 508–512 (1986). 
7.  C. S. Gandhi, E. Y. Isacoff, Molecular Models of Voltage Sensing. J. Gen. Physiol. 120, 455–
463 (2002). 
8.  Y. Jiang, V. Ruta, J. Chen, A. Lee, R. MacKinnon, The principle of gating charge movement in 
a voltage-dependent K+ channel. Nature 423, 42–48 (2003). 
9.  F. Bezanilla, The Voltage Sensor in Voltage-Dependent Ion Channels. Physiol. Rev. 80, 555–
592 (2000). 
 59 
10.  F. Bezanilla, E. Perozo, E. Stefani, Gating of Shaker K+ channels: II. The components of 
gating currents and a model of channel activation. Biophys. J. 66, 1011–1021 (1994). 
11.  Z. Lu, A. M. Klem, Y. Ramu, Coupling between Voltage Sensors and Activation Gate in 
Voltage-gated K+ Channels. J. Gen. Physiol. 120, 663–676 (2002). 
12.  E. Perozo, D. M. Cortes, L. G. Cuello, Three-dimensional architecture and gating mechanism 
of a K+ channel studied by EPR spectroscopy. Nat. Struct. Mol. Biol. 5, 459–469 (1998). 
13.  J. Payandeh, T. Scheuer, N. Zheng, W. A. Catterall, The crystal structure of a voltage-gated 
sodium channel. Nature 475, 353–358 (2011). 
14.  Q. Li, et al., Structural mechanism of voltage-dependent gating in an isolated voltage-
sensing domain. Nat. Struct. Mol. Biol. 21, 244–252 (2014). 
15.  X. Zhang, et al., Crystal structure of an orthologue of the NaChBac voltage-gated sodium 
channel. Nature 486, 130–134 (2012). 
16.  S. B. Long, E. B. Campbell, R. Mackinnon, Crystal structure of a mammalian voltage-
dependent Shaker family K+ channel. Science 309, 897–903 (2005). 
17.  V. Yarov-Yarovoy, D. Baker, W. A. Catterall, Voltage sensor conformations in the open and 
closed states in rosetta structural models of K+ channels. Proc. Natl. Acad. Sci. 103, 7292–
7297 (2006). 
18.  V. Yarov-Yarovoy, et al., Structural basis for gating charge movement in the voltage sensor 
of a sodium channel. Proc. Natl. Acad. Sci. 109, E93–E102 (2012). 
 60 
19.  A. F. Kintzer, R. M. Stroud, Structure, inhibition and regulation of two-pore channel TPC1 
from Arabidopsis thaliana. Nature 531, 258–264 (2016). 
20.  J. Guo, et al., Structure of the voltage-gated two-pore channel TPC1 from Arabidopsis 
thaliana. Nature 531, 196–201 (2016). 
21.  A. F. Kintzer, R. M. Stroud, On the structure and mechanism of two-pore channels. FEBS J. 
285, 233–243 (2018). 
22.  R. Hedrich, I. Marten, TPC1 – SV Channels Gain Shape. Mol. Plant 4, 428–441 (2011). 
23.  S. Patel, Function and dysfunction of two-pore channels. Sci Signal 8, re7–re7 (2015). 
24.  X. Wang, et al., TPC proteins are phosphoinositide- activated sodium-selective ion channels 
in endosomes and lysosomes. Cell 151, 372–383 (2012). 
25.  Y. Sakurai, et al., Two-pore channels control Ebola virus host cell entry and are drug targets 
for disease treatment. Science 347, 995–998 (2015). 
26.  C. Cang, B. Bekele, D. Ren, The voltage-gated sodium channel TPC1 confers endolysosomal 
excitability. Nat. Chem. Biol. 10, 463–469 (2014). 
27.  R. Hedrich, E. Neher, Cytoplasmic calcium regulates voltage-dependent ion channels in 
plant vacuoles. Nature 329, 833–836 (1987). 
28.  D. Beyhl, et al., The fou2 mutation in the major vacuolar cation channel TPC1 confers 
tolerance to inhibitory luminal calcium. Plant J. 58, 715–723 (2009). 
 61 
29.  C. Schulze, H. Sticht, P. Meyerhoff, P. Dietrich, Differential contribution of EF-hands to the 
Ca2+-dependent activation in the plant two-pore channel TPC1. Plant J. 68, 424–432 
(2011). 
30.  J. Frauenfeld, et al., A saposin-lipoprotein nanoparticle system for membrane proteins. Nat. 
Methods 13, 345–351 (2016). 
31.  P. K. Dominik, et al., Conformational Chaperones for Structural Studies of Membrane 
Proteins Using Antibody Phage Display with Nanodiscs. Structure 24, 300–309 (2016). 
32.  S. Wu, et al., Fabs enable single particle cryoEM studies of small proteins. Struct. Lond. Engl. 
1993 20, 582–592 (2012). 
33.  J. Guo, W. Zeng, Y. Jiang, Tuning the ion selectivity of two-pore channels. Proc. Natl. Acad. 
Sci. 114, 1009–1014 (2017). 
34.  W. A. Catterall, G. Wisedchaisri, N. Zheng, The Chemical Basis for Electrical Signaling. Nat. 
Chem. Biol. 13, 455–463 (2017). 
35.  J. She, et al., Structural insights into the voltage and phospholipid activation of the 
mammalian TPC1 channel. Nature 556, 130–134 (2018). 
36.  L. Tang, et al., Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ 
antagonist drugs. Nature 537, 117–121 (2016). 
37.  L. Zhang, et al., Ionic liquid-based ultrasound-assisted extraction of fangchinoline and 
tetrandrine from Stephaniae tetrandrae. J. Sep. Sci. 32, 3550–3554 (2009). 
 62 
38.  P. V. K. Gutla, A. Boccaccio, A. De Angeli, F. Gambale, A. Carpaneto, Modulation of plant TPC 
channels by polyunsaturated fatty acids. J. Exp. Bot. 63, 6187–6197 (2012). 
39.  E. Cao, M. Liao, Y. Cheng, D. Julius, TRPV1 structures in distinct conformations reveal 
activation mechanisms. Nature 504, 113–118 (2013). 
40.  N. Larisch, et al., The function of the two-pore channel TPC1 depends on dimerization of its 
carboxy-terminal helix. Cell. Mol. Life Sci. 73, 2565–2581 (2016). 
41.  F. J. D. Alvarez, C. Orelle, A. L. Davidson, Functional Reconstitution of an ABC Transporter in 
Nanodiscs for Use in Electron Paramagnetic Resonance Spectroscopy. J. Am. Chem. Soc. 
132, 9513–9515 (2010). 
42.  M. T. Borowska, P. K. Dominik, S. A. Anghel, A. A. Kossiakoff, R. J. Keenan, A YidC-like 
Protein in the Archaeal Plasma Membrane. Struct. Lond. Engl. 1993 23, 1715–1724 (2015). 
43.  L. J. Bailey, et al., Locking the Elbow: Improved Antibody Fab Fragments as Chaperones for 
Structure Determination. J. Mol. Biol. (2017) https:/doi.org/10.1016/j.jmb.2017.12.012. 
44.  E. A. Kabat, T. T. Wu, C. Foeller, H. M. Perry, K. S. Gottesman, Sequences of Proteins of 
Immunological Interest (DIANE Publishing, 1992). 
45.  T. K. Ritchie, et al., “Chapter Eleven - Reconstitution of Membrane Proteins in Phospholipid 
Bilayer Nanodiscs” in Methods in Enzymology, Liposomes, Part F., N. Düzgünes, Ed. 
(Academic Press, 2009), pp. 211–231. 
 63 
46.  T. Kawate, E. Gouaux, Fluorescence-detection size-exclusion chromatography for 
precrystallization screening of integral membrane proteins. Struct. Lond. Engl. 1993 14, 
673–681 (2006). 
47.  K. R. Miller, et al., T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody 
Fragment. PLOS ONE 7, e43746 (2012). 
48.  P. K. Dominik, A. A. Kossiakoff, Phage display selections for affinity reagents to membrane 
proteins in nanodiscs. Methods Enzymol. 557, 219–245 (2015). 
49.  F. A. Fellouse, et al., High-throughput generation of synthetic antibodies from highly 
functional minimalist phage-displayed libraries. J. Mol. Biol. 373, 924–940 (2007). 
50.  K. Zhang, Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016). 
51.  S. H. W. Scheres, RELION: implementation of a Bayesian approach to cryo-EM structure 
determination. J. Struct. Biol. 180, 519–530 (2012). 
52.  S. Q. Zheng, et al., MotionCor2: anisotropic correction of beam-induced motion for 
improved cryo-electron microscopy. Nat. Methods 14, 331 (2017). 
53.  A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for rapid 
unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017). 
54.  R. Y.-R. Wang, et al., Automated structure refinement of macromolecular assemblies from 
cryo-EM maps using Rosetta. eLife 5, e17219 (2016). 
 64 
55.  P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics. Acta Crystallogr. D 
Biol. Crystallogr. 60, 2126–2132 (2004). 
56.  P. D. Adams, et al., PHENIX : a comprehensive Python-based system for macromolecular 
structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010). 
57.  E. F. Pettersen, et al., UCSF Chimera--a visualization system for exploratory research and 
analysis. J. Comput. Chem. 25, 1605–1612 (2004). 
58.  I. W. Davis, L. W. Murray, J. S. Richardson, D. C. Richardson, MOLPROBITY: structure 
validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic 
Acids Res. 32, W615-619 (2004). 
59.  B. A. Barad, et al., EMRinger: side chain-directed model and map validation for 3D cryo-
electron microscopy. Nat. Methods 12, 943–946 (2015). 
60.  P. Gourdon, et al., HiLiDe—Systematic Approach to Membrane Protein Crystallization in 
Lipid and Detergent. Cryst. Growth Des. 11, 2098–2106 (2011). 
61.  M. D. Winn, et al., Overview of the CCP4 suite and current developments. Acta Crystallogr. 
D Biol. Crystallogr. 67, 235–242 (2011). 
62.  M. Strong, et al., Toward the structural genomics of complexes: Crystal structure of a 
PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. 103, 
8060–8065 (2006). 
 65 
63.  W. Kabsch, Automatic processing of rotation diffraction data from crystals of initially 
unknown symmetry and cell constants. J. Appl. Crystallogr. 26, 795–800 (1993). 
64.  A. J. McCoy, et al., Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 
(2007). 
 
  
 66 
Chapter 3 
 
Rapid screening of antibody fragments from recombinant phage display libraries using 
negative stain electron microscopy 
 
Contributing Authors 
Evan M. Green1, Natalia Sevillano2, Nancy Li2, Charles S. Craik2, Yifan Cheng1,3  
 
1University of California, San Francisco, Department of Biochemistry and Biophysics 
2University of California, San Francisco, Department of Pharmaceutical Chemistry  
3Howard Hughes Medical Institute 
 
 
 
 
 
 
  
 67 
Abstract 
 Recombinant antibodies are useful reagents in structural biology for a wide variety of 
proteins aiding in structure determination using single particle electron microscopy as they 
increase molecular weight, remove pseudosymmetry and reduce conformational flexibility. 
Panning for recombinant Fabs is a rapid process in which a large number of potentially useful 
Fabs can be identified in a short time frame. Currently screening Fabs from a panning to identify 
the most useful ones for structural studies is a time consuming and labor-intensive process. Here 
we describe a new small-scale immunoprecipitation-based method to rapidly characterize Fabs 
from a panning. We validate this method using three prototypical samples including a membrane 
protein, a multiprotein complex, and a small soluble protein. This technique provides 
information about the epitope that the Fab binds in addition to an estimate for the relative affinity 
of the Fab against an antigen. We believe this method will greatly accelerate the timeline from a 
panning to the structure determination of a Fab-antigen complex using single particle electron 
microscopy.       
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Introduction 
 Antibodies are powerful tools used to study a wide range of topics ranging from cell 
biology to biochemistry and structural biology due to their ability to bind a specific antigen with 
high affinity1. Traditionally antibodies have been generated using hybridoma technology where 
an animal is immunized with purified antigen and their B-cells are fused with myeloma cells2. 
Advances in panning for recombinant antibodies using phage display has greatly accelerated the 
pace at which potential binders can be found compared to animal-based immunizations3,4. A 
typical panning can produce dozens of potential binders that must be validated and characterized 
creating a bottleneck in the identification of useful new antigens. A number of biochemical 
techniques including the enzyme-linked immunosorbent assay (ELISA) can help triage initial 
hits but further validation is typically required to confirm complex formation between the 
antibody and antigen5. 
Structural biology has benefited from antibodies where they have been used as co-
crystallization chaperones of difficult targets to either trap relevant conformational states or to 
aid in crystal contacts6,7. For structural studies full length antibodies are typically too flexible 
requiring the use of antibody fragments - such as the variable fragment (Fv) or antigen-binding 
fragment (Fab) - or nanobodies which are single chain Vh domains found in camelids. Recently 
Fabs have been used to solve the structure of numerous targets using single-particle cryogenic 
electron microscopy (cryoEM)8–13. In this role the antibodies aid as fiducial markers to increase 
molecular weight, break pseudosymmetry, and alter orientation distributions.   
If the antibody is to be used for structural studies they need to be characterized beyond a 
simple ELISA to validate complex formation using other biochemical characterization such as 
co-elution on a size exclusion column (SEC) with the antigen. In order to generate enough 
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material for SEC runs it typically requires the purification of at least 100 ug of the antibody. 
Purification on this scale can represent a bottleneck in the screening process for many 
laboratories. To reduce this bottleneck in screening we have developed a new protocol taking 
advantage of the minimal sample requirements for negative-stain electron microscopy (nsEM) 
where a typical grid only requires approximately 25 ng of protein. This technique has been 
optimized to take advantage of the recombinant antibody panning construct design using the 
engineered affinity tags and expressions systems such that the phage display library does not 
require modification. The negative stain data collected from this new experimental protocol 
provides useful information about the interaction between the antibody and antigen including the 
location of the epitope and relative binding affinity under conditions used for subsequent 
structure determination. 
 
Results and Discussion 
In order to rapidly screen Fabs identified from recombinant panning using phage display 
libraries we developed a new immunoprecipitation-based method combined with negative stain 
electron microscopy. The method shown takes advantage of the observation that a small amount 
Fabs are secreted into the supernatant (Figure 1). Using the secreted Fabs we are able to do a 
pulldown on the myc peptide included in the original Fab panning library. To validate this 
approach, we applied the technique to several samples representing a wide range of proteins 
including a membrane protein (TmrAB), a multiprotein complex (ESCRT-I), and a small soluble 
protein (uPA). 
As an initial validation of the new screening method we set out to characterize previously 
identified Fabs against the heterodimeric ABC transporter TmrAB. A previous panning against 
TmrAB was performed to identify Fabs against the protein to aid in the structure determination 
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of the psuedosymmetric protein complex using single particle cryoEM14. The original panning 
identified almost two dozen Fabs but only a small subset were extensively characterized due to 
the time involved in purifying the necessary quantities of protein required for traditional 
screening. Using the new approach, we were able to characterize 13 new Fabs against TmrAB 
from the initial screening (Figure 2). Each Fab was expressed in small scale from E coli. and 
purified using anti-myc magnetic beads. Using only 200 ng of TmrAB for each sample we could 
identify co-complexes using negative stain EM. The gentle elution with 0.05 mg/mL of myc 
peptide did not cause excessive background for negative stain. Of the 13 Fabs tested 11 yielded 
well resolved two-dimensional class averages indicating complex formation between the Fab and 
TmrAB. The remaining 2 Fabs, BC10 and CH4, had very low particle counts likely due to low 
affinity between TmrAB and the Fab. For 9 of the Fabs we were able to generate ab initio 
reconstructions of the TmrAB-Fab complex to gain insights into the orientation of binding 
relative to TmrAB. In all cases the Fab bound to the nucleotide binding domain of the 
transporter. Due to the resolution limits of negative stain EM it is not possible to identify 
whether the Fab binds to TmrA or TmrB. With the new approach we were able to characterize 14 
Fabs in approximately one week including the expression, sample preparation, data collection 
and processing. 
We next sought to test the approach for Fabs against the endosomal sorting complexes 
required for transport (ESCRT)-I core complex, a four protein heterotetrameric assembly15. 
Similar to the approach described for TmrAB we were able to validate the method against 
previously characterized Fabs (Figure 3). From the 2D class averages it is clear that CB4 and 
DD11 bind the hinge between the stalk and the headpiece while DB8 binds only the headpiece. 
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With these complexes ab initio structure determination was not successful, likely due to the high 
flexibility of the ESCRT-I complex. 
Finally, we wanted to characterize the ability of the approach with a small soluble 
protein. We decided to use uPA, which is approximately  25 kDa, for this test as a series of Fabs 
with inhibitory properties had been generated from the parental Fab U33 with a wide range of 
affinities16. Initial characterization of the uPA-Fab complexes revealed a tri-lobed structure 
characteristic of the expected architecture (Figure 4). When analyzing the data, we observed that 
the number of particles in the full uPA-Fab complex seemed to correlate with the relative affinity 
of the Fabs making us wonder if it would be possible to directly estimate the relative affinities of 
the Fabs from the negative stain data. In order to estimate the affinities of the various Fabs we 
took advantage of the single particle nature of the data. First, we generated reference volumes for 
the Fab, uPa, and uPA-Fab complex using cryoSPARC from manually selected 2D class 
averages. Then, we merged all of the data sets together and performed a round of heterogenous 
refinement to classify each particle into one of the three classes. Using the particle counts for 
each sample it was possible to estimate the affinity by noting that the dissociation constant (Kd) 
is given by the following equation: 
Kd = [uPA][Fab] / [uPA-Fab] (eq. 1) 
If we assume that the particle counts for the negative stain data are proportional to the 
concentrations of species in solution we can estimate the relative Kd from a single concentration 
as we directly observe all required parameters. Using these results, we could then compare the 
estimated Kd values from the EM data with previously determined Kd values. From this we 
observed a high degree of correlation between the estimated and experimentally determined 
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values suggesting it is possible to directly estimate the relative affinities of each Fab from single 
particle counting.  
 
Conclusions 
 Taking advantage of negative stain EM we were able to create a new simple protocol for 
the rapid characterization of Fabs identified from phage display panning. Using this method we 
show that it provides comparable results to previous methods where each Fab is purified in large 
quantity before forming a complex with the antigen. This approach makes it possible to not only 
characterize if an identified Fab is a true binder but also gives information into the epitope that 
the Fab binds. Additionally, we show that directly from the negative stain data it is possible to 
estimate the relative affinity of the Fabs from a sample at a single concentration. This new 
method greatly improves the speed at which Fabs can be characterized and used for further 
structural studies decreasing the time-consuming bottleneck of validating Fabs after a panning.   
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Figure 3.1:  Overview of small-scale immunoprecipitation-based screening of Fabs from 
recombinant phage display libraries. Individual clones are picked and Fabs are expressed in 
small scale. Fabs secreted into the supernatant are bound to anti-myc magnetic beads and 
thoroughly washed. Antigen is added to form a complex with the Fab and unbound antigen is 
removed. The Fab-antigen complex is eluted with myc peptide and used directly to make 
negative stain EM grids for subsequent screening.   
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Figure 3.2: Screening Fabs against the heterodimeric ABC transporter TmrAB. Fabs from a 
panning against TmrAB were screened using the immunoprecipitation approach. (a) Two-
dimensional class averages of apo TmrAB and complexes between a number of unique Fabs. 
Antibodies marked with an asterisk (*) had extremely low particle counts and likely represent 
false positives or antibodies with low affinity. (b) Three-dimensional reconstruction of TmrAB 
bound to the previously reported antibody AH5. The volume in transparent blue is from negative 
stain EM data collected in this report with the cryoEM structure of TmrAB from EMDB-6085 
shown in grey. (c) Three dimensional reconstructions of TmrAB-Fab complexes from negative 
stain EM.  
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Figure 3.3: Fabs against the ESCRT-I core complex. (a) Micrograph of ESCRT-I core 
complex with DD11. (b) Two-dimensional class averages of Fabs against the ESCRT-I core 
complex.  
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Figure 3.4: Analysis for affinity matured Fabs against uPA. (a) Representative micrographs 
of negatively stained sample from the uPA-Fab pulldown. (b) Representative two-dimensional 
class averages of uPA-Fab complexes, Fab alone, and uPA alone. (c) Three dimensional volumes 
for uPA-Fab complex, Fab, and uPA used for heterogeneous classification in cryoSPARC. (d) 
Comparison of experimentally measured affinity of Fabs and calculated affinity from 
heterogenous refinement.  
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Methods 
Immunoprecipitation of antibody fragments. For the small-scale immunoprecipitation of Fabs 
1 mL of E. coli supernatant expression individual Fabs was mixed with 5 uL of anti-c-myc 
magnetic beads pre-washed in HBS (20 mM Hepes pH 7.5, 150 mM NaCl). The supernatant and 
beads were incubated for 2 hours at 4C with rotations. After binding the beads were washed 
three times with 1 mL of HBS. Following the wash 10 uL of antigen was added at a 
concentration of 0.2 mg/mL and incubated with the beads for 30 minutes at 4C. Unbound antigen 
was removed by washing two times with 1 mL of HBS. Samples were eluted with 10 uL of HBS 
supplemented with 0.1 mg/mL c-myc peptide. 
Negative stain electron microscopy. The immunoprecipitation eluent was used directly to make 
uranyl formate stained grids according to previously published protocols. Samples were imaged 
on a Tecnai T20 microscope equipped with a TVIPS 8kx8k camera at a magnification of either 
50kx or 80kx yielding a nominal magnification of 1.2 or 1.57 Å, respectively. TmrAB samples 
were imaged at 50kx magnification and uPA and ESCRT-I samples were imaged at 80kx 
magnification. All data were binned 2x directly from the camera.  
Negative stain data processing. CTF parameters were estimated using gctf and particles were 
picked using gautomatch. Two-dimensional class averages were generated using Relion. For the 
uPA samples reference volumes for heterogenous refinement were determined using the ab initio 
feature of cryoSPARC with manually selected 2D classes. After a round of 2D classification to 
remove bad particles a round of heterogenous refinement was done to classify each particle as 
either uPA alone, Fab alone, or the uPA-Fab complex. 
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